US20080107731A1 - Dpp iv inhibitor formulations - Google Patents

Dpp iv inhibitor formulations Download PDF

Info

Publication number: US20080107731A1
Authority: US; United States
Prior art keywords: pharmaceutical composition; diluent; tablet; disintegrant; lubricant
Prior art date: 2006-05-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US11/744,701

Other languages

English (en)

Inventor

Anja Kohlrausch

Patrick Romer

Gerd Seiffert

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim International GmbH

Original Assignee

Boehringer Ingelheim International GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-04

Filing date

2007-05-04

Publication date

2008-05-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36972901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080107731(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-05-04 Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH

2008-05-08 Publication of US20080107731A1 publication Critical patent/US20080107731A1/en

2010-07-13 Assigned to BOEHRINGER INGELHEIM INTERNATIONAL GMBH reassignment BOEHRINGER INGELHEIM INTERNATIONAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SEIFFERT, GERD, ROMER, PATRICK, KOHLRAUSCH, ANJA

2011-09-12 Priority to US13/230,133 priority Critical patent/US20120003313A1/en

2012-05-09 Priority to US13/467,505 priority patent/US20120219622A1/en

2013-01-07 Priority to US13/735,078 priority patent/US20130122089A1/en

2015-10-07 Priority to US14/877,019 priority patent/US20160022687A1/en

2017-07-20 Priority to US15/655,269 priority patent/US20170312287A1/en

2019-03-19 Priority to US16/357,357 priority patent/US11033552B2/en

2021-05-13 Priority to US17/319,325 priority patent/US12178819B2/en

2024-11-12 Priority to US18/944,220 priority patent/US20250064818A1/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

the present invention relates to pharmaceutical compositions of selected DPP IV inhibitors, their preparation and their use to treat selected medical conditions.
DPP-IV dipeptidyl peptidase IV
CD26 The enzyme DPP-IV (dipeptidyl peptidase IV) also known as CD26 is a serine protease known to lead to the cleavage of a dipeptide from the N-terminal end of a number of proteins having at their N-terminal end a prolin or alanin residue. Due to this property DPP-IV inhibitors interfere with the plasma level of bioactive peptides including the peptide GLP-1 and are considered to be promising drugs for the treatment of diabetes mellitus.
DPP-IV inhibitors with a primary or secondary amino group show incompatibilities, degradation problems, or extraction problems with a number of customary excipients such as microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, tartaric acid, citric acid, glucose, fructose, saccharose, lactose, maltodextrines.
customary excipients such as microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, tartaric acid, citric acid, glucose, fructose, saccharose, lactose, maltodextrines.
the compounds themselves are very stable, they react with many excipients used in solid dosage forms and with impurities of excipients, especially in tight contact provided in tablets and at high excipient/drug ratios.
a pharmaceutical composition according to the present invention is intended for the treatment of to achieve glycemic control in a type 1 or type 2 diabetes mellitus patient and comprises a DPP-IV inhibitor with an amino group, especially a free or primary amino group, as an active ingredient, a first and second diluent, a binder, a disintegrant and a lubricant.
An additional disintegrant and an additional glidant are a further option.
the compositions can be used to treat rheumatoid arthritis, obesity and osteoporosis as well as to support allograft transplantation.
Diluents suitable for a pharmaceutical composition according to the invention are cellulose powder, dibasic calciumphosphate anhydrous, dibasic calciumphosphate dihydrate, erythritol, low substituted hydroxypropyl cellulose, mannitol, pregelatinized starch or xylitol. Among those diluents mannitol and pregelatinized starch are preferred.
Diluents preferred as the second diluent are the above mentioned diluents pre-gelatinized starch and low-substituted hydroxypropylcellulose (L-HPC) which show additional binder properties.
Lubricants suitable for a pharmaceutical composition according to the invention are talc, polyethyleneglycol, calcium behenate, calcium stearate, hydrogenated castor oil or magnesium stearate.
the preferred lubricant is magnesium stearate.
Binders suitable for a pharmaceutical composition according to the invention are copovidone (copolymerisates of vinylpyrrolidon with other vinylderivates), hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyvinylpyrrolidon (povidone), pregelatinized starch, low-substituted hydroxypropylcellulose (L-HPC), copovidone and pregelatinized starch being preferred.
binders pregelatinized starch and L-HPC show additional diluent and disintegrant properties and can also be used as the second diluent or the disintegrant.
Disintegrants suitable for a pharmaceutical composition according to the present invention are corn starch, crospovidone, low-substituted hydroxypropylcellulose (L-HPC) or pregelatinized starch, corn starch being preferred.
colloidal silicon dioxide can be used as an optional glidant colloidal silicon dioxide.
An exemplary composition according to the present invention comprises the diluent mannitol, pregelatinized starch as a diluent with additional binder properties, the binder copovidone, the disintegrant corn starch, and magnesium stearate as the lubricant.
Dosage forms prepared with a pharmaceutical compositions according to the present invention contain active ingredients in dosage ranges of 0.1-100 mg. Preferred dosages are 0.5 mg, 1 mg, 2.5 mg, 5 mg and 10 mg.
Typical pharmaceutical compositions comprise (% by weight)
active ingredient 40-88% diluent 1, 3-40% diluent 2, 1-5% binder, 5-15% disintegrant, and 0.1-4% lubricant.
Preferred pharmaceutical compositions comprise (% by weight)
compositions according to the invention are intended for oral use and can be used in the dosage form of a capsule, a tablet or a film-coated tablet.
the film coat represents 2-4%, preferably 3% of the composition and comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments.
An exemplary coat composition may comprise hydroxypropylmethyl-cellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and optionally iron oxide.
DPP-IV inhibitors with a primary amino group and salts thereof such as any DPP-IV inhibitor and salt thereof defined by formula (I)
R1 is ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl], (quinoxalin-6-yl)methyl, (4-Methyl-quinazolin-2-yl)methyl, 2-Cyano-benzyl, (3-Cyano-quinolin-2-yl)methyl, (3-Cyano-pyridin-2-yl)methyl, (4-Methyl-pyrimidin-2-yl)methyl, or (4,6-Dimethyl-pyrimidin-2-yl)methyl, and R2 is 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino or (2-(S)-amino-propyl)-methylamino.
Preferred DPP IV inhibitor compounds are the following compounds and salts thereof:
compositions according to the invention can be prepared by a wet granulation process.
Alternative methods for granulation of active ingredient and excipients with a granulation liquid are fluid bed granulation or one-pot granulation.
the granulation liquid is a solvent such as water, ethanol, methanol, isopropanol, acetone, preferably purified water, and contains a binder such as copovidone.
the solvent is a volatile component, which does not remain in the final product.
the active ingredient and the other excipients with exception of the lubricant are premixed and granulated with the aqueous granulation liquid using a high shear granulator.
the wet granulation step is followed by an optional wet sieving step, drying and dry sieving of the granules. For example a fluid bed dryer can then be used for drying.
the dried granules are sieved through an appropriate sieve.
a suitable conventional blender such as a free fall blender followed by addition of the lubricant such as magnesium stearate and final blending in the blender.
an exemplary wet granulation process for the preparation of a pharmaceutical composition according to the present invention comprises
part of the exipients such as part of a disintegrant (e.g. corn starch) or a diluent (e.g. pregelatinized starch) or an additional disintegrant (crospovidone) can be added extragranular prior to final blending of step g.
a disintegrant e.g. corn starch
a diluent e.g. pregelatinized starch
an additional disintegrant crospovidone
the granulate produced in steps a to e is produced in a one pot high shear granulation process and subsequent drying in a one pot granulator.
the final blend is further filled into capsules.
the final blend is further compressed into tablets of the target tablet core weight with appropriate size and crushing strength, using an appropriate tablet press.
a coating suspension is prepared and the compressed tablet cores are coated with the coating suspension to a weight gain of about 2-4%, preferably about 3%, using a standard film coater.
the film-coating solvent is a volatile component, which does not remain in the final product.
An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press.
the following compositions can be obtained:
Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 1.000 2.000 2.500 2.000 Mannitol 43.250 86.500 108.125 86.500 Pregelatinized starch 5.000 10.000 12.500 10.000 Magnesium stearate 0.750 1.500 1.875 1.500 Total 50.000 100.000 125.000 100.000
Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 5.000 2.000 10.000 2.000 Mannitol 216.250 86.500 432.500 86.500
An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press.
the following compositions can be obtained:
Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 10.000 1.667 10.000 2.222 Dibasic 464.000 77.333 344.000 76.788 calciumphosphate, anhydrous Low-substituted 120.000 20.000 90.000 20.000 hydroxypropylcellulose Magnesium stearate 6.000 1.000 6.000 1.000 Total 600.000 100.000 450.000 100.000
Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
An active DPP IV inhibitor ingredient with a primary amino group, mannitol and part of the pregelatinized starch are blended in a suitable mixer, to produce a pre-mix.
the pre-mix is moistened with the granulation liquid and subsequently granulated.
the moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm.
the granulate is dried at 55 ° C. in a suitable dryer to a residual moisture content corresponding to 2-5% loss on drying.
the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
the granulate is blended with part of the pregelatinized starch in a suitable mixer.
Magnesium stearate is added to this blend after passing through a 1.0 mm sieve for delumping.
the final blend is produced by final blending in a suitable mixer and compressed into tablets.
the following tablet composition can be obtained:
Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
An active DPP IV inhibitor ingredient with a primary amino group, mannitol, pregelatinized starch and corn starch are blended in a suitable mixer to produce the pre-mix.
the pre-mix is moistened with the granulation liquid and subsequently granulated using a high shear mixer.
the moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm.
the granulate is dried at about 60° C. in a fluid bed dryer until a loss on the drying value of 2-4% is obtained.
the Final Blend is compressed into tablet cores.
Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension.
the tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets.
the following tablet compositions can be obtained:
Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
An active DPP IV inhibitor ingredient with a primary amino group, mannitol and pregelatinized starch are blended in a suitable mixer to produce a pre-mix.
the pre-mix is moistened with the granulation liquid and subsequently granulated.
the moist granulate is optionally sieved through a suitable sieve.
the granulate is dried at about 50° C. in a suitable dryer until a loss on drying value of 3-5% is obtained.
the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
Magnesium stearate is passed through a 1.0 mm sieve and added to the granulate. Subsequently the final blend is produced by final blending in a suitable blender and the final blend is compressed into tablets.
the following tablet compositions can be obtained:
Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
An active DPP IV inhibitor ingredient with a primary amino group and a part of mannitol, pregelatinized starch and corn starch are blended in a suitable mixer, to produce a pre-mix.
the pre-mix is moistened with the granulation liquid and subsequently granulated.
the moist granulate is sieved through a suitable sieve.
the granulate is dried at about 60° C. inlet air temperature in a fluid bed dryer until a loss on drying value of 1-4% is obtained.
the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
Magnesium stearate is passed through a sieve for delumping and added to the granulate. Additionally the remaining part of the exipients are added extragranular at this process step. Subsequently the final blend is produced by final blending in a suitable blender and compressed into tablet cores.
Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension.
the tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets.
the following formulation variants can be obtained:
Formulation E Component mg/Tablet %/Tablet mg/Tablet %/Tablet Active ingredient 1.000 1.111 1.000 1.111 Mannitol 23.300 25.889 66.950 74.389 Pregelatinized starch 4.500 5.000 4.500 5.000 Corn starch 4.500 5.000 4.500 5.000 Copovidone 1.350 1.500 2.700 3.000 Total (granulate) 34.650 38.500 79.650 88.500 Corn starch 4.500 5.000 4.500 5.000 4.500 5.000 Mannitol 45.000 50.000 Magnesium stearate 1.350 1.500 1.350 1.500 Total (tablet core) 90.000 100.000 90.000 100.000 100.000

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Obesity (AREA)
Immunology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nutrition Science (AREA)
Physiology (AREA)

US11/744,701 2006-05-04 2007-05-04 Dpp iv inhibitor formulations Abandoned US20080107731A1 (en)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
US13/230,133 US20120003313A1 (en)	2006-05-04	2011-09-12	Dpp iv inhibitor formulations
US13/467,505 US20120219622A1 (en)	2006-05-04	2012-05-09	Dpp iv inhibitor formulations
US13/735,078 US20130122089A1 (en)	2006-05-04	2013-01-07	Dpp iv inhibitor formulations
US14/877,019 US20160022687A1 (en)	2006-05-04	2015-10-07	Dpp iv inhibitor formulations
US15/655,269 US20170312287A1 (en)	2006-05-04	2017-07-20	Dpp iv inhibitor formulations
US16/357,357 US11033552B2 (en)	2006-05-04	2019-03-19	DPP IV inhibitor formulations
US17/319,325 US12178819B2 (en)	2006-05-04	2021-05-13	DPP IV inhibitor formulations
US18/944,220 US20250064818A1 (en)	2006-05-04	2024-11-12	Dpp iv inhibitor formulations

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06009201A EP1852108A1 (en)	2006-05-04	2006-05-04	DPP IV inhibitor formulations
EP06009201		2006-05-04

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US13/230,133 Continuation US20120003313A1 (en)	2006-05-04	2011-09-12	Dpp iv inhibitor formulations

Publications (1)

Publication Number	Publication Date
US20080107731A1 true US20080107731A1 (en)	2008-05-08

Family

ID=36972901

Family Applications (9)

Application Number	Title	Priority Date	Filing Date
US11/744,701 Abandoned US20080107731A1 (en)	2006-05-04	2007-05-04	Dpp iv inhibitor formulations
US13/230,133 Abandoned US20120003313A1 (en)	2006-05-04	2011-09-12	Dpp iv inhibitor formulations
US13/467,505 Abandoned US20120219622A1 (en)	2006-05-04	2012-05-09	Dpp iv inhibitor formulations
US13/735,078 Abandoned US20130122089A1 (en)	2006-05-04	2013-01-07	Dpp iv inhibitor formulations
US14/877,019 Abandoned US20160022687A1 (en)	2006-05-04	2015-10-07	Dpp iv inhibitor formulations
US15/655,269 Abandoned US20170312287A1 (en)	2006-05-04	2017-07-20	Dpp iv inhibitor formulations
US16/357,357 Active US11033552B2 (en)	2006-05-04	2019-03-19	DPP IV inhibitor formulations
US17/319,325 Active US12178819B2 (en)	2006-05-04	2021-05-13	DPP IV inhibitor formulations
US18/944,220 Pending US20250064818A1 (en)	2006-05-04	2024-11-12	Dpp iv inhibitor formulations

Family Applications After (8)

Application Number	Title	Priority Date	Filing Date
US13/230,133 Abandoned US20120003313A1 (en)	2006-05-04	2011-09-12	Dpp iv inhibitor formulations
US13/467,505 Abandoned US20120219622A1 (en)	2006-05-04	2012-05-09	Dpp iv inhibitor formulations
US13/735,078 Abandoned US20130122089A1 (en)	2006-05-04	2013-01-07	Dpp iv inhibitor formulations
US14/877,019 Abandoned US20160022687A1 (en)	2006-05-04	2015-10-07	Dpp iv inhibitor formulations
US15/655,269 Abandoned US20170312287A1 (en)	2006-05-04	2017-07-20	Dpp iv inhibitor formulations
US16/357,357 Active US11033552B2 (en)	2006-05-04	2019-03-19	DPP IV inhibitor formulations
US17/319,325 Active US12178819B2 (en)	2006-05-04	2021-05-13	DPP IV inhibitor formulations
US18/944,220 Pending US20250064818A1 (en)	2006-05-04	2024-11-12	Dpp iv inhibitor formulations

Country Status (36)

Country	Link
US (9)	US20080107731A1 (es)
EP (5)	EP1852108A1 (es)
JP (8)	JP5478244B2 (es)
KR (5)	KR102051281B1 (es)
CN (2)	CN101437493B (es)
AR (2)	AR060755A1 (es)
AT (1)	ATE480228T1 (es)
AU (1)	AU2007247193B2 (es)
BR (2)	BRPI0722388B1 (es)
CA (1)	CA2649922C (es)
CL (2)	CL2012002522A1 (es)
CY (2)	CY1111354T1 (es)
DE (1)	DE602007009091D1 (es)
DK (3)	DK2277509T5 (es)
EA (2)	EA016559B1 (es)
EC (1)	ECSP088800A (es)
ES (3)	ES2538818T3 (es)
HR (2)	HRP20100507T1 (es)
HU (1)	HUE025210T2 (es)
IL (2)	IL195030A (es)
ME (2)	ME01941B (es)
MX (3)	MX384206B (es)
MY (2)	MY146969A (es)
NO (1)	NO343067B1 (es)
NZ (3)	NZ613426A (es)
PE (2)	PE20110666A1 (es)
PL (3)	PL2023902T4 (es)
PT (2)	PT2023902E (es)
RS (2)	RS53570B1 (es)
SG (1)	SG171649A1 (es)
SI (2)	SI2283819T1 (es)
TW (2)	TWI520753B (es)
UA (1)	UA94942C2 (es)
UY (1)	UY30319A1 (es)
WO (1)	WO2007128724A1 (es)
ZA (1)	ZA200808361B (es)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060142310A1 (en) *	2004-11-05	2006-06-29	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US20070259900A1 (en) *	2006-05-04	2007-11-08	Peter Sieger	Polymorphs
US20080255159A1 (en) *	2002-08-21	2008-10-16	Boehringer Ingelheim Pharma Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20080312243A1 (en) *	2004-06-24	2008-12-18	Matthias Eckhardt	Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20090131432A1 (en) *	2002-08-22	2009-05-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivates, their preparation and their use in pharmaceutical compositions
US20090137801A1 (en) *	2004-02-18	2009-05-28	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7667035B2 (en)	2004-05-10	2010-02-23	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US20100144703A1 (en) *	2002-11-08	2010-06-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20100209506A1 (en) *	2009-02-13	2010-08-19	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20110152342A1 (en) *	2008-08-14	2011-06-23	Hiroshi Uchida	Stabilized pharmaceutical composition
US20110195917A1 (en) *	2007-08-16	2011-08-11	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US20110237526A1 (en) *	2009-09-30	2011-09-29	Boehringer Ingelheim International Gmbh	Method for the preparation of a crystalline form
US20110236477A1 (en) *	2009-10-02	2011-09-29	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US8071583B2 (en)	2006-08-08	2011-12-06	Boehringer Ingelheim International Gmbh	Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
US8106060B2 (en)	2005-07-30	2012-01-31	Boehringer Ingelheim International Gmbh	8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8232281B2 (en)	2006-05-04	2012-07-31	Boehringer Ingelheim International Gmbh	Uses of DPP-IV inhibitors
US8513264B2 (en)	2008-09-10	2013-08-20	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
US8846695B2 (en)	2009-01-07	2014-09-30	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US8853156B2 (en)	2008-08-06	2014-10-07	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients inappropriate for metformin therapy
US8865729B2 (en)	2008-12-23	2014-10-21	Boehringer Ingelheim International Gmbh	Salt forms of a xanthine compound
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
US9149478B2 (en)	2010-06-24	2015-10-06	Boehringer Ingelheim International Gmbh	Diabetes therapy
US20150283248A1 (en) *	2014-04-02	2015-10-08	Aurobindo Pharma Ltd.	Pharmaceutical compositions of Linagliptin and process for preparation thereof
US9155705B2 (en)	2008-04-03	2015-10-13	Boehringer Ingelheim International Gmbh	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9186392B2 (en)	2010-05-05	2015-11-17	Boehringer Ingelheim International Gmbh	Combination therapy
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9457029B2 (en)	2009-11-27	2016-10-04	Boehringer Ingelheim International Gmbh	Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en)	2008-08-06	2016-11-08	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients inappropriate for metformin therapy
US9526730B2 (en)	2012-05-14	2016-12-27	Boehringer Ingelheim International Gmbh	Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9713618B2 (en)	2012-05-24	2017-07-25	Boehringer Ingelheim International Gmbh	Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9873714B2 (en)	2009-09-30	2018-01-23	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US9949997B2 (en)	2013-04-05	2018-04-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9949998B2 (en)	2013-04-05	2018-04-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20180185291A1 (en)	2011-03-07	2018-07-05	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions
US10155000B2 (en)	2016-06-10	2018-12-18	Boehringer Ingelheim International Gmbh	Medical use of pharmaceutical combination or composition
US10406172B2 (en)	2009-02-13	2019-09-10	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US10548848B2 (en) *	2015-06-17	2020-02-04	Hexal Ag	Alogliptin formulation
US10555939B2 (en)	2009-05-19	2020-02-11	Celgene Corporation	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US11033552B2 (en)	2006-05-04	2021-06-15	Boehringer Ingelheim International Gmbh	DPP IV inhibitor formulations
EP2482812B1 (en)	2009-10-02	2023-01-11	Boehringer Ingelheim International GmbH	Pharmaceutical compositions comprising bi-1356 and metformin
US11666590B2 (en)	2013-04-18	2023-06-06	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11911388B2 (en)	2008-10-16	2024-02-27	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US12263153B2 (en)	2016-11-10	2025-04-01	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US12312352B2 (en)	2012-05-14	2025-05-27	Boehringer Ingelheim International Gmbh	Use of a DPP-4 inhibitor in SIRS and/or sepsis
US12433906B2 (en)	2013-04-05	2025-10-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2530113B2 (ja)	1994-06-29	1996-09-04	インターナショナル・ビジネス・マシーンズ・コーポレイション	デ―タ転送制御用インタ―フェ―ス回路及び磁気ディスク装置
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
CA2651519A1 (en)	2006-06-06	2007-12-13	Intra-Cellular Therapies, Inc.	Organic compounds
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8846693B2 (en)	2007-12-06	2014-09-30	Intra-Cellular Therapies, Inc.	Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones
MX370599B (es)	2008-08-15	2019-12-18	Boehringer Ingelheim Int	Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
WO2010038695A1 (ja) *	2008-09-30	2010-04-08	大洋薬品工業株式会社	圧縮成型製剤およびその製造方法
CA2740398A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
WO2010065152A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
CA2740385A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
US8404727B2 (en)	2009-01-07	2013-03-26	Glenmark Pharmaceuticals S.A.	Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
AR075204A1 (es)	2009-01-29	2011-03-16	Boehringer Ingelheim Int	Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
JP2012517977A (ja) *	2009-02-13	2012-08-09	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
WO2011074660A1 (ja)	2009-12-18	2011-06-23	田辺三菱製薬株式会社	溶出安定性製剤
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja)	2010-03-18	2013-06-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
JP5031054B2 (ja) *	2010-03-18	2012-09-19	信越化学工業株式会社	低置換度ヒドロキシプロピルセルロース及びこれを含む固形製剤
PH12012502161A1 (en) *	2010-05-05	2019-07-17	Boehringer Ingelheim Int	Pharmaceutical formulations comprising pioglitazone and linagliptin
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
WO2011153135A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2683700B1 (de)	2011-03-08	2015-02-18	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8785455B2 (en)	2011-05-10	2014-07-22	Sandoz Ag	Polymorph of linagliptin benzoate
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130172244A1 (en)	2011-12-29	2013-07-04	Thomas Klein	Subcutaneous therapeutic use of dpp-4 inhibitor
JP6374862B2 (ja)	2012-05-24	2018-08-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
WO2013174769A1 (en)	2012-05-25	2013-11-28	Boehringer Ingelheim International Gmbh	Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
CN104519874B (zh)	2012-06-05	2018-08-03	武田药品工业株式会社	固体制剂
US9867829B2 (en)	2012-08-13	2018-01-16	Sandoz Ag	Stable pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof
WO2014045266A1 (en)	2012-09-24	2014-03-27	Ulf Eriksson	Treatment of type 2 diabetes and related conditions
WO2014051024A1 (ja) *	2012-09-27	2014-04-03	株式会社三和化学研究所	アナグリプチン含有医薬組成物
JP6283314B2 (ja) *	2012-09-27	2018-02-21	株式会社三和化学研究所	アナグリプチン含有固形製剤
WO2014051023A1 (ja) *	2012-09-27	2014-04-03	株式会社三和化学研究所	アナグリプチン含有製剤
US20150297573A1 (en)	2012-10-24	2015-10-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
WO2014065427A1 (ja) *	2012-10-26	2014-05-01	株式会社三和化学研究所	アナグリプチン含有固形製剤
WO2014080384A1 (en)	2012-11-26	2014-05-30	Ranbaxy Laboratories Limited	Pharmaceutical composition of linagliptin
AU2014230096C1 (en)	2013-03-15	2019-08-29	Boehringer Ingelheim International Gmbh	Use of linagliptin in cardio- and renoprotective antidiabetic therapy
EP2848241A1 (en)	2013-09-12	2015-03-18	Sanovel Ilac Sanayi ve Ticaret A.S.	Effervescent formulations of linagliptin
EP2848242A1 (en)	2013-09-12	2015-03-18	Sanovel Ilac Sanayi ve Ticaret A.S.	Orally disintegrating formulations of Linagliptin
TR201310724A2 (tr)	2013-09-12	2015-03-23	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Linagliptinin farmasotik formulasyonları.
WO2015110962A1 (en)	2014-01-21	2015-07-30	Wockhardt Limited	Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
CN105878349A (zh) *	2014-11-28	2016-08-24	于凯	一种预防和治疗糖尿病引起的骨质疏松的组合物
ES2805743T3 (es)	2015-03-24	2021-02-15	Inst Nat Sante Rech Med	Método y composición farmacéutica para uso en el tratamiento de la diabetes
EP3359136A1 (en) *	2015-10-09	2018-08-15	Hexal AG	Pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof
EP3156048A1 (en)	2015-10-13	2017-04-19	Galenicum Health S.L.	Stable pharmaceutical composition of linagliptin in the form of immediate release tablets
US9727330B2 (en) *	2015-11-25	2017-08-08	Red Hat, Inc.	Source to image transformation pipeline for a platform-as-a-service system
CN105853382B (zh) *	2016-05-19	2019-07-19	广州迈达康医药科技有限公司	一种利格列汀口崩片及其制备方法
CN106236754A (zh) *	2016-07-31	2016-12-21	合肥远志医药科技开发有限公司	一种包含利格列汀活性成分的组合物及其制备方法
CN106137991A (zh) *	2016-08-01	2016-11-23	合肥远志医药科技开发有限公司	一种利格列汀片制粒方法
US11285180B2 (en)	2016-12-06	2022-03-29	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
EP3668515A4 (en) *	2017-08-18	2021-05-12	Abbvie Inc.	PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROMAS, POLYCYSTIC OVARY SYNDROME OR ADENOMYOSIS
EP3801539A4 (en) *	2018-06-01	2022-02-23	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF LINAGLIPTIN
CN113165338B (zh) *	2018-10-05	2023-04-11	埃斯普投资有限公司	包含水溶性纤维素醚的光滑的高固体膜包衣组合物及其制备工艺
EP4045048A4 (en)	2019-10-14	2023-05-24	Santa Farma Ilaç Sanayi A.S.	ORAL FORMULATIONS COMPRISING SITAGLIPTIN HCI MONOHYDRATE WITH ENHANCED PHARMACEUTICAL CHARACTERISTICS
WO2021109970A1 (zh) *	2019-12-02	2021-06-10	成都苑东生物制药股份有限公司	一种黄嘌呤衍生物药物组合物及其制备方法
WO2023002036A1 (en)	2021-07-22	2023-01-26	Krka, D.D., Novo Mesto	Process for preparing a pharmaceutical composition comprising linagliptin and metformin hydrochloride
KR20230126664A (ko)	2022-02-23	2023-08-30	주식회사 제뉴원사이언스	리나글립틴 또는 이의 약학적으로 허용가능한 염과 메트포르민 또는 이의 약학적으로 허용가능한 염을 포함하는 약물방출이 조절된 약제학적 복합제제
CN115227661B (zh) *	2022-09-22	2022-12-13	北京惠之衡生物科技有限公司	一种利格列汀片及其制备方法
WO2024091863A1 (en)	2022-10-25	2024-05-02	Starrock Pharma Llc	Combinatorial, and rotational combinatorial therapies for obesity and other diseases
WO2025227129A2 (en)	2024-04-25	2025-10-30	Starrock Pharma Llc	Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof

Citations (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2056046A (en) *	1933-05-19	1936-09-29	Rhone Poulenc Sa	Manufacture of bases derived from benz-dioxane
US2375138A (en) *	1942-05-01	1945-05-01	American Cyanamid Co	Alkamine esters of aryloxymethyl benzoic acid
US2629736A (en) *	1951-02-24	1953-02-24	Searle & Co	Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
US2730544A (en) *	1952-07-23	1956-01-10	Sahyun Lab	Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
US2750387A (en) *	1953-11-25	1956-06-12	Searle & Co	Basically substituted derivatives of diarylaminobenzamides
US2928833A (en) *	1959-03-03	1960-03-15	S E Massengill Company	Theophylline derivatives
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3236891A (en) *	1955-11-29	1966-02-22	Oreal	Nitrophenylenediamine derivatives
US3454635A (en) *	1965-07-27	1969-07-08	Hoechst Ag	Benzenesulfonyl-ureas and process for their manufacture
US3673241A (en) *	1968-04-04	1972-06-27	Ciba Geigy Corp	Substituted benzaldehyde guanylhydrazones
US3925357A (en) *	1972-07-01	1975-12-09	Takeda Chemical Industries Ltd	' -sulfobenzylpenicillin salt
US4005208A (en) *	1975-05-16	1977-01-25	Smithkline Corporation	N-Heterocyclic-9-xanthenylamines
US4599338A (en) *	1984-01-17	1986-07-08	Adir, S.A.R.L.	Antimigraine 8-[3-(4-aminocarbonyl piperazino and piperidino) propyl[xanthines
US4687777A (en) *	1985-01-19	1987-08-18	Takeda Chemical Industries, Ltd.	Thiazolidinedione derivatives, useful as antidiabetic agents
US4873330A (en) *	1984-06-25	1989-10-10	Orion-Yhtyma Oy	A process for the preparation of anhydrous, stable, crystalline delta-form of prazosin hydrochloride
US5041448A (en) *	1985-06-24	1991-08-20	Janssen Pharmaceutica N.V.	(4-piperidinylmethyl and -hetero) purines
US5051517A (en) *	1989-05-20	1991-09-24	Bayer Aktiengesellschaft	Process for the preparation of herbicidally active 3-amino-5-aminocarbonyl-1,2,4-triazoles
US5084460A (en) *	1990-12-24	1992-01-28	A. H. Robins Company, Incorporated	Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
US5223499A (en) *	1989-05-30	1993-06-29	Merck & Co., Inc.	6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5234897A (en) *	1989-03-15	1993-08-10	Bayer Aktiengesellschaft	Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
US5258380A (en) *	1985-06-24	1993-11-02	Janssen Pharmaceutica N.V.	(4-piperidinylmethyl and -hetero)purines
US5266555A (en) *	1991-07-20	1993-11-30	Bayer Aktiengesellschaft	Substituted triazoles
US5300298A (en) *	1992-05-06	1994-04-05	The Pennsylvania Research Corporation	Methods of treating obesity with purine related compounds
US5329025A (en) *	1988-09-21	1994-07-12	G. D. Searle & Co.	3-azido compound
US5332744A (en) *	1989-05-30	1994-07-26	Merck & Co., Inc.	Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5389642A (en) *	1992-12-16	1995-02-14	Merck Patent Gesellschaft Mit Beschrankter Haftung	Imidazopyridines
US5399578A (en) *	1990-02-19	1995-03-21	Ciba-Geigy Corp	Acyl compounds
US5470579A (en) *	1989-11-28	1995-11-28	Lvmh, Recherche	Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation
US5719279A (en) *	1992-08-10	1998-02-17	Boehringer Ingelheim Kg	Asymmetrically substituted xanthines
US5753635A (en) *	1996-08-16	1998-05-19	Berlex Laboratories, Inc.	Purine derivatives and their use as anti-coagulants
US6303661B1 (en) *	1996-04-25	2001-10-16	Probiodrug	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
US6342601B1 (en) *	1997-12-05	2002-01-29	Astrazeneca Ab	Compounds
US20020161001A1 (en) *	2000-07-04	2002-10-31	Kanstrup Anders Bendtz	Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US20020169174A1 (en) *	2000-09-19	2002-11-14	Samuel Chackalamannil	Xanthine phosphodiesterase V inhibitors
US20020198205A1 (en) *	2001-02-24	2002-12-26	Frank Himmelsbach	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US6548481B1 (en) *	1998-05-28	2003-04-15	Probiodrug Ag	Effectors of dipeptidyl peptidase IV
US20030105077A1 (en) *	2001-07-03	2003-06-05	Kanstrup Anders Bendtz	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US6579868B1 (en) *	1998-01-05	2003-06-17	Eisai Co., Ltd.	Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
US20030166578A1 (en) *	2000-06-19	2003-09-04	Arch Jonathan Robert Sanders	Combinations od dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US20030199528A1 (en) *	2001-09-19	2003-10-23	Kanstrup Anders B.	Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV
US20030224043A1 (en) *	2002-02-01	2003-12-04	Pfizer Inc.	Immediate release dosage forms containing solid drug dispersions
US20030232987A1 (en) *	2002-05-31	2003-12-18	Schering Corporation	Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
US20030236272A1 (en) *	2002-01-11	2003-12-25	Carr Richard David	Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
US20040082570A1 (en) *	2002-02-25	2004-04-29	Eisai Co., Ltd.	Xanthine derivative and DPPIV inhibitor
US20040097510A1 (en) *	2002-08-21	2004-05-20	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20040116328A1 (en) *	2002-06-06	2004-06-17	Eisai Co., Ltd.	Condensed imidazole derivatives
US20040122228A1 (en) *	2002-08-22	2004-06-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	New purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040126358A1 (en) *	2002-09-16	2004-07-01	Warne Nicholas W.	Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
US20040138214A1 (en) *	2002-11-08	2004-07-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138215A1 (en) *	2002-11-21	2004-07-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040166125A1 (en) *	2002-08-22	2004-08-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US6784195B2 (en) *	2000-02-05	2004-08-31	Vertex Pharmaceuticals Incorporated	Pyrazole compositions useful as inhibitors of ERK
US20050020574A1 (en) *	2002-12-03	2005-01-27	Boehringer Ingelheim Pharma Gmbh Co. Kg	New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US20050026921A1 (en) *	2003-06-18	2005-02-03	Boehringer Ingelheim International Gmbh	New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US20050032804A1 (en) *	2003-06-24	2005-02-10	Cypes Stephen Howard	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20050070594A1 (en) *	2003-07-31	2005-03-31	Boehringer Ingelheim International Gmbh	Use of angiotensin II receptor antagonists
US20050130985A1 (en) *	2003-11-27	2005-06-16	Boehringer Ingelheim International Gmbh	8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition
US20050171093A1 (en) *	2003-12-17	2005-08-04	Boehringer Ingelheim International Gmbh	New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions
US20050187227A1 (en) *	2004-02-23	2005-08-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US20050203095A1 (en) *	2004-03-13	2005-09-15	Boehringer Ingelheim International Gmbh	Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20050234108A1 (en) *	2004-02-18	2005-10-20	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20050261352A1 (en) *	2004-05-10	2005-11-24	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US20050266080A1 (en) *	2004-05-28	2005-12-01	Desai Divyakant S	Coated tablet formulation and method
US20060004074A1 (en) *	2004-06-24	2006-01-05	Boehringer Ingelheim International Gmbh	New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20060039974A1 (en) *	2002-09-11	2006-02-23	Takeda Pharmaceutical Company Limited	Sustained release preparation
US20060058323A1 (en) *	2004-09-11	2006-03-16	Boehringer Ingelheim International Gmbh	New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060079541A1 (en) *	2004-09-14	2006-04-13	Boehringer Ingelheim International Gmbh	3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060094722A1 (en) *	2002-09-26	2006-05-04	Eisai Co., Ltd.	Combination drug
US7060722B2 (en) *	2000-08-10	2006-06-13	Mitsubishi Pharma Corporation	Proline derivatives and use thereof as drugs
US20060142310A1 (en) *	2004-11-05	2006-06-29	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US20070027168A1 (en) *	2005-07-30	2007-02-01	Waldemar Pfrengle	8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US7179809B2 (en) *	2004-04-10	2007-02-20	Boehringer Ingelheim International Gmbh	2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7183280B2 (en) *	2003-12-23	2007-02-27	Boehringer Ingelheim International Gmbh	Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions
US20070093659A1 (en) *	2003-12-18	2007-04-26	Jean-Francois Bonfanti	Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
US20070185091A1 (en) *	1999-06-21	2007-08-09	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them
US20070219178A1 (en) *	2003-12-04	2007-09-20	Eisai Co., Ltd.	Preventive or therapeutic agents for multiple sclerosis
US20070281940A1 (en) *	2006-05-04	2007-12-06	Klaus Dugi	Uses of dpp-iv inhibitors

Family Cites Families (421)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES385302A1 (es)	1970-10-22	1973-04-16	Miquel S A Lab	Procedimiento para la obtencion de derivados trisubstitui- dos de etilendiamina.
DE2205815A1 (de)	1972-02-08	1973-08-16	Hoechst Ag	Piperazinderivate und verfahren zu ihrer herstellung
US4061753A (en)	1976-02-06	1977-12-06	Interx Research Corporation	Treating psoriasis with transient pro-drug forms of xanthine derivatives
AU508480B2 (en)	1977-04-13	1980-03-20	Asahi Kasei Kogyo Kabushiki Kaisha	Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2758025A1 (de)	1977-12-24	1979-07-12	Bayer Ag	Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
DE2929596A1 (de)	1979-07-21	1981-02-05	Hoechst Ag	Verfahren zur herstellung von oxoalkyl-xanthinen
GB2084580B (en)	1980-10-01	1984-07-04	Glaxo Group Ltd	Aminoalkyl furan derivative
US4382091A (en)	1981-04-30	1983-05-03	Syntex (U.S.A.) Inc.	Stabilization of 1-substituted imidazole derivatives in talc
JPS6130567A (ja)	1984-07-23	1986-02-12	Shiseido Co Ltd	尿素の安定化法
JPS61124383A (ja)	1984-11-16	1986-06-12	Unitika Ltd	固定化線維素溶解活性酵素の安定化法
CA1242699A (en)	1985-02-01	1988-10-04	Bristol-Myers Company	Cefbuperazone and derivatives thereof
DE3688827T2 (de)	1985-10-25	1994-03-31	Beecham Group Plc	Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
US5034225A (en)	1985-12-17	1991-07-23	Genentech Inc.	Stabilized human tissue plasminogen activator compositions
US5433959A (en)	1986-02-13	1995-07-18	Takeda Chemical Industries, Ltd.	Stabilized pharmaceutical composition
ATE72244T1 (de)	1986-03-21	1992-02-15	Heumann Pharma Gmbh & Co	Kristalline, wasserfreie sigma -form von 2-(4-(2furoyl-(2-piperazin)-1-yl>-4-amino-6,7- dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
EP1498425A1 (en)	1986-05-05	2005-01-19	The General Hospital Corporation	Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
AU619444B2 (en)	1986-06-02	1992-01-30	Nippon Chemiphar Co. Ltd.	2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
US4968672A (en)	1987-01-02	1990-11-06	The United States Of America As Represented By The Department Of Health And Human Services	Adenosine receptor prodrugs
US4743450A (en)	1987-02-24	1988-05-10	Warner-Lambert Company	Stabilized compositions
JPS63273159A (ja)	1987-04-30	1988-11-10	Sharp Corp	文字処理装置
JPS6440433A (en)	1987-08-05	1989-02-10	Green Cross Corp	Aqueous liquid composition of thrombin
EP0342675B1 (en)	1988-05-19	1995-01-25	Chugai Seiyaku Kabushiki Kaisha	Novel quinolonecarboxylic acid derivatives
DE3926119A1 (de)	1989-08-08	1991-02-14	Bayer Ag	3-amino-5-aminocarbonyl-1,2,4-triazol-derivate
GB8906792D0 (en)	1989-03-23	1989-05-10	Beecham Wuelfing Gmbh & Co Kg	Treatment and compounds
IL94390A (en)	1989-05-30	1996-03-31	Merck & Co Inc	The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU208115B (en)	1989-10-03	1993-08-30	Biochemie Gmbh	New process for producting pleuromutilin derivatives
KR930000861B1 (ko)	1990-02-27	1993-02-08	한미약품공업 주식회사	오메프라졸 직장투여 조성물
DE69104453T2 (de)	1990-09-13	1995-03-16	Akzo Nv	Stabilisierte feste chemische Zusammensetzungen.
GB9020959D0 (en)	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
US5602127A (en)	1991-02-06	1997-02-11	Karl Thomae Gmbh	(Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5594003A (en)	1991-02-06	1997-01-14	Dr. Karl Thomae Gmbh	Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5614519A (en)	1991-02-06	1997-03-25	Karl Thomae Gmbh	(1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
GB9109862D0 (en)	1991-05-08	1991-07-03	Beecham Lab Sa	Pharmaceutical formulations
WO1993008259A2 (en)	1991-10-22	1993-04-29	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type iv
GB9215633D0 (en)	1992-07-23	1992-09-09	Smithkline Beecham Plc	Novel treatment
DE69318077T2 (de)	1992-07-31	1998-10-29	Shionogi & Co	Triazolylthiomethylthiocephalosporin-Hydrochlorid, sein kristallines Hydrat und seine Herstellung
US5358941A (en)	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
WO1994015605A1 (en)	1993-01-14	1994-07-21	Cell Therapeutics, Inc.	Acetal or ketal substituted therapeutic compounds
EP0638567A4 (en)	1993-02-18	1995-05-10	Kyowa Hakko Kogyo Kk	ADENOSINE INHIBITORS.
JP3726291B2 (ja)	1993-07-05	2005-12-14	三菱ウェルファーマ株式会社	安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
FR2707641B1 (fr)	1993-07-16	1995-08-25	Fournier Ind & Sante	Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
DE4339868A1 (de)	1993-11-23	1995-05-24	Merck Patent Gmbh	Imidazopyridazine
DE4404183A1 (de)	1994-02-10	1995-08-17	Merck Patent Gmbh	4-Amino-1-piperidylbenzoylguanidine
US5545745A (en)	1994-05-23	1996-08-13	Sepracor, Inc.	Enantioselective preparation of optically pure albuterol
CO4410190A1 (es)	1994-09-19	1997-01-09	Lilly Co Eli	3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
DE69531623T2 (de)	1994-10-12	2004-06-17	Euroceltique S.A.	Neue benzoxazole
GB9501178D0 (en)	1995-01-20	1995-03-08	Wellcome Found	Guanine derivative
WO1996036638A1 (en)	1995-05-19	1996-11-21	Chiroscience Limited	Xanthines and their therapeutic use
JPH08333339A (ja)	1995-06-08	1996-12-17	Fujisawa Pharmaceut Co Ltd	光学活性なピペリジン酢酸誘導体の製造法
GB9523752D0 (en)	1995-11-21	1996-01-24	Pfizer Ltd	Pharmaceutical formulations
DE19543478A1 (de)	1995-11-22	1997-05-28	Bayer Ag	Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
FR2742751B1 (fr)	1995-12-22	1998-01-30	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
NZ326238A (en)	1995-12-26	1999-11-29	Alteon Inc	Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
US5891855A (en)	1996-02-12	1999-04-06	The Scripps Research Institute	Inhibitors of leaderless protein export
TW518219B (en)	1996-04-26	2003-01-21	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
WO1997046526A1 (en)	1996-06-07	1997-12-11	Eisai Co., Ltd.	Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US5965555A (en)	1996-06-07	1999-10-12	Hoechst Aktiengesellschaft	Xanthine compounds having terminally animated alkynol side chains
US5958951A (en)	1996-06-14	1999-09-28	Novo Nordiskials	Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
RS49597B (sr)	1996-09-23	2007-06-04	Eli Lilly And Company,	Olanzapin dihidrat d
JP2001502703A (ja)	1996-10-28	2001-02-27	ノボノルディスクアクティーゼルスカブ	（−）―３，４―トランス―ジアリールクロマンの調製方法
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
DE69737916T2 (de)	1996-11-12	2008-04-03	Novo Nordisk A/S	Verwendung von GLP-1 Peptiden
GB9623859D0 (en)	1996-11-15	1997-01-08	Chiroscience Ltd	Novel compounds
PT948358E (pt)	1996-12-24	2004-10-29	Biogen Idec Inc	Formulacoes de interferao liquidas e estaveis
DE19705233A1 (de)	1997-02-12	1998-08-13	Froelich Juergen C	Verfahren zur Herstellung einer Formulierung enthaltend Arginin
US6011049A (en)	1997-02-19	2000-01-04	Warner-Lambert Company	Combinations for diabetes
US6248758B1 (en)	1997-03-13	2001-06-19	Hexal Ag	Pharmaceutical antacid
US5972332A (en)	1997-04-16	1999-10-26	The Regents Of The University Of Michigan	Wound treatment with keratinocytes on a solid support enclosed in a porous material
ZA984697B (en)	1997-06-13	1999-12-01	Lilly Co Eli	Stable insulin formulations.
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6174548B1 (en)	1998-08-28	2001-01-16	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
TW589174B (en)	1997-12-10	2004-06-01	Takeda Chemical Industries Ltd	Agent for treating high-risk impaired glucose tolerance
JPH11193270A (ja)	1997-12-26	1999-07-21	Koei Chem Co Ltd	光学活性１−メチル−３−ピペリジンメタノールの製造方法
US6803357B1 (en)	1998-02-02	2004-10-12	New England Medical Center Hospitals, Inc.	Method of regulating glucose metabolism, and reagents related thereto
US20030013740A1 (en)	1998-03-27	2003-01-16	Martin P. Redmon	Stable dosage forms of fluoxetine and its enantiomers
KR20010042078A (ko)	1998-03-31	2001-05-25	도쿠시마 히데이치	피리다지논 염산염 화합물 및 그 제조방법
EP0950658A1 (en)	1998-04-13	1999-10-20	Takeda Chemical Industries, Ltd.	2-Pipirazinone-1-acetic acid dihydrochloride derivative used to inhibit platelet aggregation
US6207207B1 (en)	1998-05-01	2001-03-27	Mars, Incorporated	Coated confectionery having a crispy starch based center and method of preparation
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
CA2337015C (en)	1998-07-15	2004-09-07	Asahi Kasei Kogyo Kabushiki Kaisha	Excipient
GB9827133D0 (en)	1998-12-09	1999-02-03	Zeneca Ltd	Chemical process
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
IT1312018B1 (it)	1999-03-19	2002-04-04	Fassi Aldo	Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina.
WO2000066101A2 (en)	1999-04-30	2000-11-09	City Of Hope	Method of inhibiting glycation product formation
US20040152659A1 (en)	1999-05-12	2004-08-05	Fujisawa Pharmaceutical Co. Ltd.	Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AU4431000A (en)	1999-05-12	2000-12-05	Fujisawa Pharmaceutical Co., Ltd.	Novel use
AU5294100A (en)	1999-05-27	2000-12-18	University Of Virginia Patent Foundation	Method and compositions for treating the inflammatory response
KR100767473B1 (ko)	1999-05-31	2007-10-17	미쯔비시 가가꾸 가부시끼가이샤	간실질세포 증식인자 동결건조 제제
JP4156807B2 (ja)	1999-06-01	2008-09-24	エランファーマインターナショナル，リミティド	小型ミル及びその方法
US6545002B1 (en)	1999-06-01	2003-04-08	University Of Virginia Patent Foundation	Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6448323B1 (en)	1999-07-09	2002-09-10	Bpsi Holdings, Inc.	Film coatings and film coating compositions based on polyvinyl alcohol
ES2166270B1 (es)	1999-07-27	2003-04-01	Almirall Prodesfarma Sa	Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
GB9928330D0 (en)	1999-11-30	2000-01-26	Ferring Bv	Novel antidiabetic agents
KR20100130651A (ko)	1999-12-23	2010-12-13	노파르티스 아게	당 대사 장애를 치료하기 위한 혈당강하제의 용도
WO2001051919A2 (en)	2000-01-07	2001-07-19	Transform Pharmaceuticals, Inc.	High-throughput formation, identification, and analysis of diverse solid-forms
US6362172B2 (en)	2000-01-20	2002-03-26	Bristol-Myers Squibb Company	Water soluble prodrugs of azole compounds
ES2436610T3 (es)	2000-01-21	2014-01-03	Novartis Ag	Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
JP4621326B2 (ja) *	2000-02-01	2011-01-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	テプレノンの安定化組成物
EP1295609A4 (en)	2000-02-24	2004-11-03	Takeda Chemical Industries Ltd	MEDICINES WITH MIXED ACTIVE SUBSTANCES
EP1132389A1 (en)	2000-03-06	2001-09-12	Vernalis Research Limited	New aza-indolyl derivatives for the treatment of obesity
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0006133D0 (en)	2000-03-14	2000-05-03	Smithkline Beecham Plc	Novel pharmaceutical
JP2001278812A (ja) *	2000-03-27	2001-10-10	Kyoto Pharmaceutical Industries Ltd	錠剤用崩壊剤及びこれを用いた錠剤
US6399101B1 (en)	2000-03-30	2002-06-04	Mova Pharmaceutical Corp.	Stable thyroid hormone preparations and method of making same
ES2525041T3 (es)	2000-03-31	2014-12-16	Royalty Pharma Collection Trust	Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
US7282219B2 (en)	2000-03-31	2007-10-16	Kirin Beer Kabushiki Kaisha	Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
JP2001292388A (ja)	2000-04-05	2001-10-19	Sharp Corp	再生装置
GB0008694D0 (en)	2000-04-07	2000-05-31	Novartis Ag	Organic compounds
EP1295873A4 (en)	2000-06-14	2004-05-19		METHODS OF PRODUCING RACEMIC PIPERIDINE DERIVATIVE AND PRODUCING OPTICALLY ACTIVE PIPERIDINE DERIVATIVE
GB0014969D0 (en)	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
US6689353B1 (en)	2000-06-28	2004-02-10	Bayer Pharmaceuticals Corporation	Stabilized interleukin 2
US20060034922A1 (en)	2000-11-03	2006-02-16	Andrx Labs, Llc	Controlled release metformin compositions
US6722883B2 (en)	2000-11-13	2004-04-20	G & H Technologies Llc	Protective coating for abrasive dental tools and burs
US6821261B2 (en)	2000-12-12	2004-11-23	Dj Orthopedics, Llc	Orthopedic brace having length-adjustable supports
EP1354882A1 (en)	2000-12-27	2003-10-22	Kyowa Hakko Kogyo Co., Ltd.	Dipeptidyl peptidase iv inhibitor
FR2818906B1 (fr)	2000-12-29	2004-04-02	Dospharma	Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
FR2819254B1 (fr)	2001-01-08	2003-04-18	Fournier Lab Sa	Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
DE10109021A1 (de)	2001-02-24	2002-09-05	Boehringer Ingelheim Pharma	Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10117803A1 (de)	2001-04-10	2002-10-24	Boehringer Ingelheim Pharma	Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
PL364221A1 (en)	2001-02-02	2004-12-13	Takeda Chemical Industries, Ltd.	Fused heterocyclic compounds
US6649187B2 (en)	2001-02-16	2003-11-18	Bristol-Myers Squibb Pharma Company	Use of polyalkylamine polymers in controlled release devices
US6610326B2 (en)	2001-02-16	2003-08-26	Andrx Corporation	Divalproex sodium tablets
US6936590B2 (en)	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
US6693094B2 (en)	2001-03-22	2004-02-17	Chrono Rx Llc	Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
JP2002348279A (ja)	2001-05-25	2002-12-04	Nippon Kayaku Co Ltd	光学活性ピリジルケトン誘導体の製造方法並びに光学活性ピリジルケトン誘導体
DE10130371A1 (de)	2001-06-23	2003-01-02	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0115517D0 (en)	2001-06-25	2001-08-15	Ferring Bv	Novel antidiabetic agents
DE60221983T2 (de)	2001-06-27	2008-05-15	Smithkline Beecham Corp.	Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
CZ20033521A3 (en)	2001-06-27	2004-05-12	Smithklineábeechamácorporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
JP2005502624A (ja)	2001-07-03	2005-01-27	ノボ　ノルディスク　アクティーゼルスカブ	糖尿病を治療するための、ｄｐｐ−ｉｖを阻害するプリン誘導体
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003006424A1 (en)	2001-07-10	2003-01-23	4Sc Ag	Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7085258B2 (en) *	2001-07-19	2006-08-01	International Business Machines Corporation	Instant messaging with voice conversation feature
US6955933B2 (en)	2001-07-24	2005-10-18	Lumileds Lighting U.S., Llc	Light emitting diodes with graded composition active regions
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
AR035119A1 (es)	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
CA2460512A1 (en)	2001-09-14	2003-03-27	Mitsubishi Pharma Corporation	Thiazolidine derivatives and medicinal use thereof
EP1585956A4 (en)	2001-09-24	2009-10-21	Univ Oregon Health & Science	EVALUATIONS OF NEURONS IN THE ARQUE CORE FOR THE SCREENING OF AGENTS OF MODIFICATION OF FOOD BEHAVIOR
DK1435877T3 (da)	2001-10-15	2009-08-03	Hemoteq Ag	Overtrækning af stents for at forhindre restenose
DE10151296A1 (de)	2001-10-17	2003-04-30	Boehringer Ingelheim Pharma	Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
US20030083354A1 (en)	2001-10-26	2003-05-01	Pediamed Pharmaceuticals, Inc.	Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US6861440B2 (en)	2001-10-26	2005-03-01	Hoffmann-La Roche Inc.	DPP IV inhibitors
JP2005507261A (ja)	2001-10-31	2005-03-17	ノバルティスアクチエンゲゼルシャフト	Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法
CA2363053C (en)	2001-11-09	2011-01-25	Bernard Charles Sherman	Clopidogrel bisulfate tablet formulation
CA2466870A1 (en)	2001-11-26	2003-06-05	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
US20040171836A1 (en)	2001-12-21	2004-09-02	Toshihiro Fujino	Method for producing optical-active cis-piperidine derivatives
US6727261B2 (en)	2001-12-27	2004-04-27	Hoffman-La Roche Inc.	Pyrido[2,1-A]Isoquinoline derivatives
JP3668241B2 (ja)	2001-12-28	2005-07-06	株式会社Ｎｒｌファーマ	脂質代謝改善用組成物
WO2003057235A2 (en)	2002-01-10	2003-07-17	Imperial College Innovations Ltd	Modification of feeding behavior
US20070197552A1 (en)	2002-01-11	2007-08-23	Novo Nordisk A/S	Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
EA007614B1 (ru)	2002-01-16	2006-12-29	Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг	Двухслойная фармацевтическая таблетка и способ ее получения
US8399414B2 (en)	2002-01-21	2013-03-19	Nrl Pharma, Inc.	Analgesics
EP1333033A1 (en)	2002-01-30	2003-08-06	Boehringer Ingelheim Pharma GmbH & Co.KG	FAP-activated anti-tumor compounds
US7610153B2 (en)	2002-02-13	2009-10-27	Virginia Commonwealth University	Multi-drug titration and evaluation
ES2627842T3 (es)	2002-02-21	2017-07-31	Valeant Pharmaceuticals Luxembourg S.À.R.L.	Formas de dosificación de liberación controlada
HUP0200849A2 (hu)	2002-03-06	2004-08-30	Sanofi-Synthelabo	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
JP4298212B2 (ja)	2002-03-29	2009-07-15	大日本印刷株式会社	塩酸エピナスチン高融点型結晶の製造法
JP2003300977A (ja)	2002-04-10	2003-10-21	Sumitomo Pharmaceut Co Ltd	キサンチン誘導体
WO2003088900A2 (en)	2002-04-16	2003-10-30	Merck & Co., Inc.	Solid forms of salts with tyrosine kinase activity
WO2003090783A1 (en)	2002-04-26	2003-11-06	Ajinomoto Co., Inc.	Preventive/remedy for diabetes
WO2003094909A2 (en)	2002-05-09	2003-11-20	Enos Pharmaceuticals, Inc.	Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
GB0212412D0 (en)	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
ES2199061B1 (es) *	2002-06-10	2005-02-16	Laboratorios Vita, S.A.	Comprimidos bucodispersables y procedimiento para su obtencion.
FR2840897B1 (fr)	2002-06-14	2004-09-10	Fournier Lab Sa	Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
US20040002615A1 (en)	2002-06-28	2004-01-01	Allen David Robert	Preparation of chiral amino-nitriles
US7065367B2 (en) *	2002-07-11	2006-06-20	Oliver Michaelis	Interface selection in a wireless communication network
US20040023981A1 (en)	2002-07-24	2004-02-05	Yu Ren	Salt forms with tyrosine kinase activity
TW200409746A (en)	2002-07-26	2004-06-16	Theravance Inc	Crystalline β2 adrenergic receptor agonist
ITMI20021725A1 (it)	2002-08-01	2002-10-31	Zambon Spa	Composizioni farmaceutiche ad attivita' antibiotica.
TW200404796A (en)	2002-08-19	2004-04-01	Ono Pharmaceutical Co	Nitrogen-containing compound
DE10238243A1 (de)	2002-08-21	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2058311A3 (de) *	2002-08-21	2011-04-13	Boehringer Ingelheim Pharma GmbH & Co. KG	8-[3-amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10238477A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238470A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Phenyl-substituierte Pyrazolyprimidine
JP2004123738A (ja) *	2002-09-11	2004-04-22	Takeda Chem Ind Ltd	徐放性製剤
US7262207B2 (en)	2002-09-19	2007-08-28	Abbott Laboratories	Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20060039968A1 (en) *	2002-10-08	2006-02-23	Ramalingam Manikandan	Gabapentin tablets and method for their preparation
AU2003269850A1 (en)	2002-10-08	2004-05-04	Novo Nordisk A/S	Hemisuccinate salts of heterocyclic dpp-iv inhibitors
US20040122048A1 (en)	2002-10-11	2004-06-24	Wyeth Holdings Corporation	Stabilized pharmaceutical composition containing basic excipients
US6861526B2 (en)	2002-10-16	2005-03-01	Pfizer Inc.	Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2004037169A2 (en)	2002-10-18	2004-05-06	Merck & Co., Inc.	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004161749A (ja)	2002-10-24	2004-06-10	Toray Fine Chemicals Co Ltd	光学活性含窒素化合物の製造方法
WO2004048379A1 (ja)	2002-11-01	2004-06-10	Sumitomo Pharmaceuticals Co., Ltd.	キサンチン化合物
EP1562925B1 (en)	2002-11-07	2007-01-03	Merck & Co., Inc.	Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10251927A1 (de)	2002-11-08	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
UY28103A1 (es)	2002-12-03	2004-06-30	Boehringer Ingelheim Pharma	Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
WO2004052362A1 (en)	2002-12-10	2004-06-24	Novartis Ag	Combination of an dpp-iv inhibitor and a ppar-alpha compound
US20040152720A1 (en)	2002-12-20	2004-08-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
UA83813C2 (ru)	2002-12-20	2008-08-26	Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг	Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
JP2006515882A (ja)	2003-01-08	2006-06-08	カイロンコーポレイション	組織因子経路インヒビター（ｔｆｐｉ）または組織因子経路インヒビター改変体を含有する安定化水性組成物
HRP20050696B1 (en)	2003-01-14	2008-10-31	Arena Pharmaceuticals Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2004250336A (ja) *	2003-02-18	2004-09-09	Kao Corp	コーティング錠及び糖衣錠の製造法
US7135575B2 (en)	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
US7442387B2 (en)	2003-03-06	2008-10-28	Astellas Pharma Inc.	Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
AU2004220053A1 (en)	2003-03-12	2004-09-23	Arizona Board Of Regents On Behalf Of The University Of Arizona	Weak base salts
JP2006520335A (ja)	2003-03-18	2006-09-07	ノバルティスアクチエンゲゼルシャフト	脂肪酸とアミノ酸を含有する組成物
EP1615646B2 (en)	2003-04-08	2022-07-27	Progenics Pharmaceuticals, Inc.	Pharmaceutical formulations containing methylnaltrexone
US20040220186A1 (en)	2003-04-30	2004-11-04	Pfizer Inc.	PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JPWO2004096806A1 (ja)	2003-04-30	2006-07-13	大日本住友製薬株式会社	縮合イミダゾール誘導体
WO2004104216A2 (en)	2003-05-21	2004-12-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
TW200510277A (en)	2003-05-27	2005-03-16	Theravance Inc	Crystalline form of β2-adrenergic receptor agonist
FR2855521B1 (fr)	2003-05-28	2005-08-05	Flamel Tech Sa	Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
AU2003902828A0 (en)	2003-06-05	2003-06-26	Fujisawa Pharmaceutical Co., Ltd.	Dpp-iv inhibitor
JP4210558B2 (ja)	2003-06-17	2009-01-21	三菱電機株式会社	面状光源装置および該装置を用いる表示装置
DE10327439A1 (de)	2003-06-18	2005-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
NZ544221A (en)	2003-06-20	2009-05-31	Hoffmann La Roche	Pyrido[2,1-a]-isoquinoline derivatives as DPP-IV inhibitors
RU2339636C2 (ru)	2003-06-20	2008-11-27	Ф.Хоффманн-Ля Рош Аг	Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv)
US7364755B2 (en)	2003-07-07	2008-04-29	Synthon Ip Inc.	Modified calcium phosphate excipient
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN102417508A (zh)	2003-07-14	2012-04-18	艾尼纳制药公司	作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症
US20050027012A1 (en)	2003-07-16	2005-02-03	Boehringer Ingelheim International Gmbh	Tablets containing ambroxol
WO2005009412A1 (en)	2003-07-24	2005-02-03	Wockhardt Limited	Oral compositions for treatment of diseases
CN1829709A (zh) *	2003-08-01	2006-09-06	健亚生物科技公司	对抗黄病毒的双环咪唑衍生物
US6995183B2 (en)	2003-08-01	2006-02-07	Bristol Myers Squibb Company	Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
KR101293503B1 (ko)	2003-08-14	2013-08-07	노보 노르디스크 헬스 케어 악티엔게젤샤프트	인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
WO2005023179A2 (en) *	2003-08-29	2005-03-17	Aton Pharma, Inc.	Combination methods of treating cancer
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US20070072810A1 (en)	2003-10-03	2007-03-29	Takeda Pharmaceutical Company, Limited	Agent for treating diabetes
BR0304443B1 (pt)	2003-10-28	2012-08-21		processo para obtenção de concentrados de titánio com elevado teor de tio2 e baixo teor de radionuclìdeos a partir de concentrados mecánicos de anatásio.
US7107714B2 (en)	2003-11-10	2006-09-19	Marketing Displays, Inc.	Portable snap-fit sign stand
AU2004290897B2 (en)	2003-11-17	2009-02-26	Novartis Ag	Use of dipeptidyl peptidase IV inhibitors
DE10359098A1 (de)	2003-12-17	2005-07-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
JP4958560B2 (ja)	2003-12-24	2012-06-20	プロシディオン・リミテッド	Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
JP4994043B2 (ja)	2004-01-21	2012-08-08	エランコ・アニマル・ヘルス・アイルランド・リミテッド	ミトラタピデ経口用溶液
SE0400234D0 (sv)	2004-02-06	2004-02-06	Active Biotech Ab	New compounds, methods for their preparation and use thereof
WO2005085246A1 (de)	2004-02-18	2005-09-15	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
DE102004019540A1 (de)	2004-04-22	2005-11-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
EP1593671A1 (en)	2004-03-05	2005-11-09	Graffinity Pharmaceuticals AG	DPP-IV inhibitors
CN102127057A (zh)	2004-03-15	2011-07-20	武田药品工业株式会社	二肽基肽酶抑制剂
WO2005092877A1 (de)	2004-03-16	2005-10-06	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1577306A1 (de)	2004-03-17	2005-09-21	Boehringer Ingelheim Pharma GmbH & Co.KG	Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
CA2561210A1 (en)	2004-04-10	2005-10-20	Boehringer Ingelheim International Gmbh	Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments
US20050239778A1 (en)	2004-04-22	2005-10-27	Boehringer Ingelheim International Gmbh	Novel medicament combinations for the treatment of respiratory diseases
US20050244502A1 (en)	2004-04-28	2005-11-03	Mathias Neil R	Composition for enhancing absorption of a drug and method
MXPA06012752A (es)	2004-05-03	2007-02-14	Omega Bio Pharma Ip3 Ltd	Cisteaminas para tratar complicaciones de hipercolesterolemia y diabetes.
GEP20084421B (en)	2004-05-12	2008-07-10	Pfizer Prod Inc	Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
DE102004024454A1 (de)	2004-05-14	2005-12-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
PE20060315A1 (es)	2004-05-24	2006-05-15	Irm Llc	Compuestos de tiazol como moduladores de ppar
ZA200610041B (en)	2004-06-01	2008-07-30	Ares Trading Sa	Method of stabilizing proteins
CA2569095A1 (en)	2004-06-03	2005-12-15	Pfizer Products Inc.	Crystal structure of dipeptidyl peptidase iv (dpp-iv) and uses thereof
WO2005117861A1 (en)	2004-06-04	2005-12-15	Novartis Ag	Use of organic compounds
EP1604989A1 (en)	2004-06-08	2005-12-14	Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft	DPP-IV inhibitors
WO2005120576A2 (en)	2004-06-09	2005-12-22	Yasoo Health	Composition and method for improving pancreatic islet cell survival
CA2511269A1 (en)	2004-07-07	2006-01-07	F. Hoffmann-La Roche Ag	Multimarker panel based on p1gf for diabetes type 1 and 2
JP2008506651A (ja)	2004-07-14	2008-03-06	ノバルティスアクチエンゲゼルシャフト	Ｄｐｐ−ｉｖ阻害剤と５−ｈｔ３および／または５−ｈｔ４受容体を調節する化合物の組合せ剤
JP2006045156A (ja)	2004-08-06	2006-02-16	Sumitomo Pharmaceut Co Ltd	縮合ピラゾール誘導体
TW200613275A (en)	2004-08-24	2006-05-01	Recordati Ireland Ltd	Lercanidipine salts
WO2006022428A1 (ja)	2004-08-26	2006-03-02	Takeda Pharmaceutical Company Limited	糖尿病治療剤
CN1759834B (zh)	2004-09-17	2010-06-23	中国医学科学院医药生物技术研究所	黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
CA2580461A1 (en)	2004-09-23	2006-04-06	Amgen Inc.	Substituted sulfonamidopropionamides and methods of use
CA2580266A1 (en)	2004-10-08	2006-04-20	Novartis Ag	Combination of organic compounds
KR20070073887A (ko)	2004-10-12	2007-07-10	그렌마크 파머수티칼스 에스. 아.	신규한 디펩티딜 펩티다제 ⅳ 억제제, 이를 함유하는약제학적 조성물, 및 이의 제조공정
AU2005299808B2 (en)	2004-10-25	2009-08-20	Novartis Ag	Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
DE102005013967A1 (de)	2004-11-05	2006-10-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP2006137678A (ja)	2004-11-10	2006-06-01	Shionogi & Co Ltd	インターロイキン−２組成物
CA2590912A1 (en)	2004-12-24	2006-06-29	Dainippon Sumitomo Pharma Co., Ltd.	Bicyclic pyrrole derivatives
KR100760430B1 (ko)	2004-12-31	2007-10-04	한미약품 주식회사	당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
DOP2006000008A (es)	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en)	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
GT200600008A (es)	2005-01-18	2006-08-09		Formulacion de compresion directa y proceso
WO2006111169A1 (en)	2005-04-21	2006-10-26	Gastrotech Pharma A/S	Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
MX2007011453A (es)	2005-04-22	2008-02-12	Alantos Pharmaceuticals Holding Inc	Inhibidores de la dipeptidil peptidasa-iv.
UA91546C2 (uk)	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
KR20080016671A (ko)	2005-05-25	2008-02-21	와이어쓰	치환된 3-시아노퀴놀린 및 그것의 중간체를 합성하는 방법
PT1894567E (pt)	2005-06-03	2012-11-21	Mitsubishi Tanabe Pharma Corp	Agentes farmacêuticos concomitantes e sua utilização
GT200600218A (es)	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
JP5301987B2 (ja)	2005-06-20	2013-09-25	デコード・ジェネティクス・イーエイチエフ	２型糖尿病のリスクの診断マーカーとしてのｔｃｆ７ｌ２遺伝子中の遺伝子変異体
PE20070374A1 (es)	2005-07-08	2007-05-12	Pfizer Ltd	ANTICUERPOS ANTI-MAdCAM
US20070014855A1 (en)	2005-07-12	2007-01-18	Rahul Gawande S	Stable desloratadine compositions
UY29694A1 (es)	2005-07-28	2007-02-28	Boehringer Ingelheim Int	Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
BRPI0614732A2 (pt) *	2005-08-11	2011-04-12	Hoffmann La Roche	composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados
EP1760076A1 (en)	2005-09-02	2007-03-07	Ferring B.V.	FAP Inhibitors
EP1942898B2 (en)	2005-09-14	2014-05-14	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors for treating diabetes
ES2445180T5 (es)	2005-09-14	2022-02-01	Takeda Pharmaceuticals Co	Administración de inhibidores de dipeptidil peptidasa
DE602006006461D1 (de)	2005-09-16	2009-06-04	Arena Pharm Inc	Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
CA2622579C (en)	2005-09-20	2013-12-31	Novartis Ag	Use of a dpp-iv inhibitor to reduce hypoglycemic events
WO2007038979A1 (en)	2005-09-22	2007-04-12	Swissco Development Ag	Effervescent metformin composition and tablets and granules made therefrom
JOP20180109A1 (ar)	2005-09-29	2019-01-30	Novartis Ag	تركيبة جديدة
US20080221200A1 (en)	2005-09-30	2008-09-11	Malcolm Allison	Combination of Organic Compounds
JP2009513633A (ja)	2005-10-25	2009-04-02	メルクエンドカムパニーインコーポレーテッド	糖尿病および高血圧を治療するためのジペプチジルペプチダーゼ−４インヒビターと降圧薬との組合せ
JP2009515005A (ja)	2005-11-04	2009-04-09	エルエスケーブルリミテッド	水酸化マグネシウムポリマーハイブリッド粒子の製造方法
WO2007078726A2 (en)	2005-12-16	2007-07-12	Merck & Co., Inc.	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
EP1966215A1 (en)	2005-12-23	2008-09-10	Novartis AG	Condensed heterocyclic compounds useful as dpp-iv inhibitors
US20090054512A1 (en)	2006-01-06	2009-02-26	Foley James E	Use of organic compounds
BRPI0707849A2 (pt)	2006-02-15	2011-05-10	Boehringer Ingelheim Int	derivados de benzonitrila substituÍdos por glicopiranosila, composiÇÕes farmacÊuticas contendo tais compostos, seu uso e processo para sua fabricaÇço
WO2007099345A1 (en)	2006-03-02	2007-09-07	Betagenon Ab	Medical use of bmp-2 and/ or bmp-4
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8455435B2 (en)	2006-04-19	2013-06-04	Ludwig-Maximilians-Universitat Munchen	Remedies for ischemia
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CN109503584A (zh)	2006-05-04	2019-03-22	勃林格殷格翰国际有限公司	多晶型
WO2007136650A2 (en)	2006-05-16	2007-11-29	Gilead Sciences, Inc.	Method and compositions for treating hematological malignancies
KR20070111099A (ko)	2006-05-16	2007-11-21	영진약품공업주식회사	시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
WO2007137107A2 (en)	2006-05-19	2007-11-29	Abbott Laboratories	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
KR100858848B1 (ko)	2006-05-23	2008-09-17	한올제약주식회사	메트포르민 서방정
WO2007149797A2 (en)	2006-06-19	2007-12-27	Novartis Ag	Use of organic compounds
WO2007148185A2 (en)	2006-06-21	2007-12-27	Pfizer Products Inc.	Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
AT503443B1 (de)	2006-06-23	2007-10-15	Leopold Franzens Uni Innsbruck	Verfahren zur herstellung einer eisfläche für eissportbahnen
TW200811140A (en)	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en)	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
EP2057160A1 (en)	2006-08-08	2009-05-13	Boehringer Ingelheim International GmbH	Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
JP5384343B2 (ja)	2006-08-15	2014-01-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、ｓｇｌｔ阻害剤としてのそれらの使用及びそれらの製造方法
EP2056673A4 (en)	2006-08-17	2010-06-16	Wellstat Therapeutics Corp	COMBINATION TREATMENT FOR METABOLISM DISEASES
DE102006042586B4 (de)	2006-09-11	2014-01-16	Betanie B.V. International Trading	Verfahren zum mikropartikulären Beladen von hochpolymeren Kohlenhydraten mit hydrophoben Wirkflüssigkeiten
US20080098614A1 (en)	2006-10-03	2008-05-01	Wyeth	Lyophilization methods and apparatuses
US7956201B2 (en)	2006-11-06	2011-06-07	Hoffman-La Roche Inc.	Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
CL2007003187A1 (es)	2006-11-06	2008-03-07	Boehringer Ingelheim Int	Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
UA100008C2 (ru)	2006-11-09	2012-11-12	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и фармацевтической композицией, которая их содержит
MY157365A (en)	2006-12-06	2016-05-31	Smithkline Beecham Corp	Chemical compounds and uses
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CL2008000017A1 (es)	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
CL2008000133A1 (es)	2007-01-19	2008-05-23	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
ME01239B (me)	2007-02-01	2013-06-20	Takeda Pharmaceuticals Co	Čvrsti preparat koji sadrži alogliptin i pioglitazon
CL2008000280A1 (es)	2007-02-01	2008-08-18	Takeda Pharmaceutical	Composicion farmaceutica en forma de comprimido que contiene un granulo que comprende un principio activo que induce facilmente a un problema en la compresion y celulosa microcristalina y un auxiliar de compresion que contiene estearato de magnesio y
EP2118051B1 (en)	2007-02-06	2011-05-04	Chelsea Therapeutics, Inc.	New compounds, methods for their preparation and use thereof
EP2120885A2 (en)	2007-03-13	2009-11-25	Takeda Pharmaceutical Company Limited	Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
JP2010521492A (ja)	2007-03-15	2010-06-24	ネクティド，インク．	徐放性ビグアニド組成物、および即時性ジペプチジルペプチダーゼｉｖ阻害剤組成物を含む抗糖尿病合剤
AU2008233548B2 (en)	2007-04-03	2011-12-01	Mitsubishi Tanabe Pharma Corporation	Combined use of dipeptidyl peptidase IV inhibitor compound and sweetener
US9050123B2 (en)	2007-04-16	2015-06-09	Smith & Nephew, Inc.	Powered surgical system
PE20090696A1 (es)	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
US7910583B2 (en)	2007-05-04	2011-03-22	Bristol-Myers Squibb Company	[6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
ES2398478T5 (es)	2007-07-09	2016-02-25	Symrise Ag	Sales solubles estables de ácido fenilbencimidazolsulfónico de pH 6,0 a menos de 6,8
PE20090882A1 (es)	2007-07-19	2009-08-03	Takeda Pharmaceutical	Preparacion solida que comprende alogliptina y clorhidrato de metformina
CL2008002424A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.
PE20090603A1 (es)	2007-08-16	2009-06-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20090597A1 (es)	2007-08-16	2009-06-06	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
ES2733348T3 (es)	2007-08-17	2019-11-28	Boehringer Ingelheim Int	Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
WO2009037719A1 (en)	2007-09-21	2009-03-26	Lupin Limited	Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
EP2597103B1 (en)	2007-11-16	2016-11-02	Novo Nordisk A/S	Stable pharmaceutical compositions comprising liraglutide and degludec
CN101234105A (zh)	2008-01-09	2008-08-06	北京润德康医药技术有限公司	一种含有二甲双胍和维格列汀的药用组合物及其制备方法
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US20090186086A1 (en)	2008-01-17	2009-07-23	Par Pharmaceutical, Inc.	Solid multilayer oral dosage forms
TW200936136A (en)	2008-01-28	2009-09-01	Sanofi Aventis	Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
CN101932241A (zh)	2008-02-05	2010-12-29	默沙东公司	二甲双胍和二肽基肽酶-ⅳ抑制剂的组合的药物组合物
AU2009220444A1 (en)	2008-03-04	2009-09-11	Merck Sharp & Dohme Corp.	Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
BRPI0912245A2 (pt)	2008-03-05	2019-09-24	Takeda Pharmaceuticals Co	composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
US8551524B2 (en)	2008-03-14	2013-10-08	Iycus, Llc	Anti-diabetic combinations
AU2009231906A1 (en)	2008-03-31	2009-10-08	Metabolex, Inc.	Oxymethylene aryl compounds and uses thereof
AR071175A1 (es)	2008-04-03	2010-06-02	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
CN101590007A (zh)	2008-05-27	2009-12-02	北京瑞伊人科技发展有限公司	一种盐酸二甲双胍/伏格列波糖降糖口服制剂组合物及其制备
PE20100156A1 (es)	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es)	2008-08-15	2019-12-18	Boehringer Ingelheim Int	Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
JP2010053576A (ja)	2008-08-27	2010-03-11	Sumitomo Forestry Co Ltd	舗装用マット
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
UY32177A (es)	2008-10-16	2010-05-31	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
WO2010045656A2 (en)	2008-10-17	2010-04-22	Nectid, Inc.	Novel sglt2 inhibitor dosage forms
TWI508965B (zh)	2008-12-23	2015-11-21	Boehringer Ingelheim Int	有機化合物的鹽形式
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es)	2009-01-29	2011-03-16	Boehringer Ingelheim Int	Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
JP2012517977A (ja)	2009-02-13	2012-08-09	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
UA102429C2 (ru)	2009-02-13	2013-07-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение
UY32427A (es)	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
TW201031661A (en)	2009-02-17	2010-09-01	Targacept Inc	Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
CA2754523A1 (en)	2009-03-20	2010-09-23	Pfizer Inc.	3-oxa-7-azabicyclo[3.3.1]nonanes
US8815292B2 (en)	2009-04-27	2014-08-26	Revalesio Corporation	Compositions and methods for treating insulin resistance and diabetes mellitus
JP2012525396A (ja)	2009-04-27	2012-10-22	レバレジオコーポレイション	インスリン耐性および真性糖尿病を治療するための組成物および方法
WO2010140111A1 (en)	2009-06-02	2010-12-09	Ranbaxy Laboratories Limited	Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
US20120059011A1 (en)	2009-06-15	2012-03-08	Nicholas Birringer	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
CN108938585A (zh)	2009-07-21	2018-12-07	凯克斯生物制药公司	柠檬酸铁剂型
US10610489B2 (en)	2009-10-02	2020-04-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
CA2776296C (en)	2009-10-02	2017-11-07	Boehringer Ingelheim International Gmbh	Therapeutic uses of pharmaceutical compositions
JP5446716B2 (ja)	2009-10-21	2014-03-19	大正製薬株式会社	アルギニン及びカルニチン含有錠剤の製造方法
EP2504002B1 (en)	2009-11-27	2019-10-09	Boehringer Ingelheim International GmbH	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP2010070576A (ja)	2009-12-28	2010-04-02	Sato Pharmaceutical Co Ltd	速溶解性錠剤
TWI562775B (en)	2010-03-02	2016-12-21	Lexicon Pharmaceuticals Inc	Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
JP2013522279A (ja)	2010-03-18	2013-06-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
PH12012502161A1 (en)	2010-05-05	2019-07-17	Boehringer Ingelheim Int	Pharmaceutical formulations comprising pioglitazone and linagliptin
AU2011249722B2 (en)	2010-05-05	2015-09-17	Boehringer Ingelheim International Gmbh	Combination therapy
JP5707489B2 (ja)	2010-06-09	2015-04-30	ポクセル・エスアーエスＰｏｘｅｌｓａｓ	１型糖尿病の処置
JP2013533241A (ja)	2010-06-22	2013-08-22	ティダブリューアイ・ファーマシューティカルズ・インコーポレイテッド	食物効果が減少した制御放出組成物
ES2802243T3 (es)	2010-06-24	2021-01-18	Boehringer Ingelheim Int	Terapia para la diabetes
WO2012031124A2 (en)	2010-09-03	2012-03-08	Bristol-Myers Squibb Company	Drug formulations using water soluble antioxidants
WO2012039420A1 (ja)	2010-09-21	2012-03-29	国立大学法人九州大学	動脈圧反射機能障害に関連した疾患を治療するためのバイオニック動脈圧反射システム
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012088682A1 (en)	2010-12-29	2012-07-05	Shanghai Fochon Pharmaceutical Co Ltd.	2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
MX2013008372A (es)	2011-02-01	2013-08-12	Astrazeneca Uk Ltd	Formulaciones farmaceuticas que incluyen compuesto de amina.
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8785455B2 (en)	2011-05-10	2014-07-22	Sandoz Ag	Polymorph of linagliptin benzoate
KR101985384B1 (ko)	2011-07-15	2019-06-03	베링거 인겔하임 인터내셔날 게엠베하	치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US20130172244A1 (en)	2011-12-29	2013-07-04	Thomas Klein	Subcutaneous therapeutic use of dpp-4 inhibitor
CN104040060B (zh)	2012-01-04	2017-05-17	宝洁公司	具有多个区域的含活性物质纤维结构
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6374862B2 (ja)	2012-05-24	2018-08-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
WO2013174769A1 (en)	2012-05-25	2013-11-28	Boehringer Ingelheim International Gmbh	Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
WO2013179307A2 (en)	2012-05-29	2013-12-05	Mylan Laboratories Limited	Stabilized pharmaceutical compositions of saxagliptin
EP3943084A1 (en)	2012-08-24	2022-01-26	Novartis AG	Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
EP2908806A1 (en)	2012-10-09	2015-08-26	Boehringer Ingelheim International GmbH	Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
US20140100292A1 (en)	2012-10-09	2014-04-10	Boehringer Ingelheim International Gmbh	Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets
US9050302B2 (en)	2013-03-01	2015-06-09	Jazz Pharmaceuticals Ireland Limited	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
AU2014230096C1 (en)	2013-03-15	2019-08-29	Boehringer Ingelheim International Gmbh	Use of linagliptin in cardio- and renoprotective antidiabetic therapy
MX2021004308A (es)	2013-04-18	2022-10-26	Boehringer Ingelheim Int	Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria.
US20140343014A1 (en)	2013-05-17	2014-11-20	Boehringer Ingelheim International Gmbh	Combination of a certain dpp-4 inhibitor and voglibose
CA2914791A1 (en)	2013-06-14	2014-12-18	Boehringer Ingelheim International Gmbh	Dpp-4 inhibitors for treating diabetes and its complications
CN104418857A (zh)	2013-08-22	2015-03-18	北京蓝丹医药科技有限公司	无定型利格列汀及其制备方法
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
CN104130258B (zh)	2014-08-13	2016-06-01	广东东阳光药业有限公司	一种二聚体的转化方法
WO2016059219A1 (en)	2014-10-17	2016-04-21	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20160318101A1 (en)	2014-12-02	2016-11-03	Halliburton Energy Services, Inc.	Integrated heat-exchanging mold systems
KR102442536B1 (ko)	2015-09-17	2022-09-13	한미정밀화학주식회사	리나글립틴 결정형 및 이의 제조방법
CN105272982B (zh)	2015-11-23	2017-06-16	齐鲁制药有限公司	利格列汀新晶型及其制备方法
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
KR20210032468A (ko)	2018-07-17	2021-03-24	베링거 인겔하임 인터내셔날 게엠베하	심장에 안전한 항당뇨병 요법
US11752145B2 (en)	2020-03-30	2023-09-12	Sanjay Gupta	Quinoline derivatives with other anti-viral agents

2006
- 2006-05-04 EP EP06009201A patent/EP1852108A1/en not_active Withdrawn
2007
- 2007-04-30 KR KR1020177035865A patent/KR102051281B1/ko active Active
- 2007-04-30 NZ NZ613426A patent/NZ613426A/en unknown
- 2007-04-30 NZ NZ595983A patent/NZ595983A/xx unknown
- 2007-04-30 HR HR20100507T patent/HRP20100507T1/hr unknown
- 2007-04-30 NZ NZ572862A patent/NZ572862A/en unknown
- 2007-04-30 EP EP15158445.5A patent/EP2910241A1/en not_active Withdrawn
- 2007-04-30 KR KR1020157022377A patent/KR101710881B1/ko active Active
- 2007-04-30 WO PCT/EP2007/054204 patent/WO2007128724A1/en not_active Ceased
- 2007-04-30 PL PL07728658T patent/PL2023902T4/pl unknown
- 2007-04-30 RS RSP20140606 patent/RS53570B1/sr unknown
- 2007-04-30 PT PT07728658T patent/PT2023902E/pt unknown
- 2007-04-30 UA UAA200813472A patent/UA94942C2/ru unknown
- 2007-04-30 RS RSP-2010/0457A patent/RS51466B/sr unknown
- 2007-04-30 MY MYPI20084341A patent/MY146969A/en unknown
- 2007-04-30 MX MX2018008133A patent/MX384206B/es unknown
- 2007-04-30 KR KR20087026969A patent/KR101478983B1/ko active Active
- 2007-04-30 EP EP07728658A patent/EP2023902B8/en active Active
- 2007-04-30 BR BRPI0722388-9A patent/BRPI0722388B1/pt active IP Right Grant
- 2007-04-30 PL PL10175638T patent/PL2283819T3/pl unknown
- 2007-04-30 SG SG201103141-6A patent/SG171649A1/en unknown
- 2007-04-30 EP EP10175638.5A patent/EP2283819B9/en not_active Revoked
- 2007-04-30 MX MX2011004033A patent/MX358617B/es unknown
- 2007-04-30 ES ES10175188.1T patent/ES2538818T3/es active Active
- 2007-04-30 EP EP10175188.1A patent/EP2277509B1/en not_active Revoked
- 2007-04-30 CA CA2649922A patent/CA2649922C/en active Active
- 2007-04-30 DK DK10175188.1T patent/DK2277509T5/da active
- 2007-04-30 CN CN2007800162273A patent/CN101437493B/zh not_active Ceased
- 2007-04-30 SI SI200731572T patent/SI2283819T1/sl unknown
- 2007-04-30 AT AT07728658T patent/ATE480228T1/de active
- 2007-04-30 EA EA200802184A patent/EA016559B1/ru unknown
- 2007-04-30 EA EA201100958A patent/EA029890B1/ru not_active IP Right Cessation
- 2007-04-30 CN CN201210068456.2A patent/CN102526737B/zh not_active Expired - Fee Related
- 2007-04-30 MX MX2008013958A patent/MX2008013958A/es active IP Right Grant
- 2007-04-30 KR KR1020167029877A patent/KR101855323B1/ko active Active
- 2007-04-30 AU AU2007247193A patent/AU2007247193B2/en active Active
- 2007-04-30 HU HUE10175188A patent/HUE025210T2/en unknown
- 2007-04-30 KR KR1020147011768A patent/KR20140063896A/ko not_active Ceased
- 2007-04-30 DK DK10175638.5T patent/DK2283819T3/da active
- 2007-04-30 PT PT101756385T patent/PT2283819E/pt unknown
- 2007-04-30 ES ES07728658T patent/ES2348576T3/es active Active
- 2007-04-30 PL PL10175188T patent/PL2277509T3/pl unknown
- 2007-04-30 JP JP2009508327A patent/JP5478244B2/ja active Active
- 2007-04-30 DK DK07728658.1T patent/DK2023902T3/da active
- 2007-04-30 ME MEP-2014-136A patent/ME01941B/me unknown
- 2007-04-30 SI SI200730434T patent/SI2023902T1/sl unknown
- 2007-04-30 ES ES10175638T patent/ES2527409T4/es active Active
- 2007-04-30 DE DE602007009091T patent/DE602007009091D1/de active Active
- 2007-04-30 ME MEP-2010-172A patent/ME01170B/me unknown
- 2007-04-30 BR BRPI0711179-7A patent/BRPI0711179B1/pt active IP Right Grant
- 2007-05-02 PE PE2011000193A patent/PE20110666A1/es active IP Right Grant
- 2007-05-02 PE PE2007000538A patent/PE20080698A1/es not_active Application Discontinuation
- 2007-05-03 TW TW103100247A patent/TWI520753B/zh active
- 2007-05-03 UY UY30319A patent/UY30319A1/es not_active Application Discontinuation
- 2007-05-03 TW TW096115808A patent/TWI474843B/zh active
- 2007-05-04 AR ARP070101929A patent/AR060755A1/es unknown
- 2007-05-04 US US11/744,701 patent/US20080107731A1/en not_active Abandoned
2008
- 2008-10-01 ZA ZA200808361A patent/ZA200808361B/xx unknown
- 2008-10-07 EC EC2008008800A patent/ECSP088800A/es unknown
- 2008-10-10 NO NO20084256A patent/NO343067B1/no unknown
- 2008-10-30 IL IL195030A patent/IL195030A/en unknown
- 2008-10-30 MY MYPI2011001739A patent/MY148496A/en unknown
2010
- 2010-11-30 CY CY20101101096T patent/CY1111354T1/el unknown
2011
- 2011-01-19 AR ARP110100165A patent/AR079930A2/es unknown
- 2011-05-12 IL IL212841A patent/IL212841A0/en unknown
- 2011-09-12 US US13/230,133 patent/US20120003313A1/en not_active Abandoned
2012
- 2012-01-04 JP JP2012000293A patent/JP6100998B2/ja active Active
- 2012-05-09 US US13/467,505 patent/US20120219622A1/en not_active Abandoned
- 2012-09-12 CL CL2012002522A patent/CL2012002522A1/es unknown
- 2012-09-12 CL CL2012002521A patent/CL2012002521A1/es unknown
2013
- 2013-01-07 US US13/735,078 patent/US20130122089A1/en not_active Abandoned
- 2013-07-11 JP JP2013145188A patent/JP2013227338A/ja active Pending
2015
- 2015-01-02 CY CY20151100002T patent/CY1116064T1/el unknown
- 2015-01-05 HR HRP20150003TT patent/HRP20150003T2/hr unknown
- 2015-10-07 US US14/877,019 patent/US20160022687A1/en not_active Abandoned
2016
- 2016-02-24 JP JP2016033423A patent/JP6564720B2/ja active Active
2017
- 2017-07-20 US US15/655,269 patent/US20170312287A1/en not_active Abandoned
- 2017-11-10 JP JP2017217311A patent/JP7084711B2/ja active Active
2019
- 2019-03-19 US US16/357,357 patent/US11033552B2/en active Active
2020
- 2020-02-28 JP JP2020033173A patent/JP6987908B2/ja active Active
2021
- 2021-05-13 US US17/319,325 patent/US12178819B2/en active Active
2022
- 2022-03-15 JP JP2022040337A patent/JP2022075826A/ja active Pending
2024
- 2024-02-29 JP JP2024029844A patent/JP2024074800A/ja active Pending
- 2024-11-12 US US18/944,220 patent/US20250064818A1/en active Pending

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2056046A (en) *	1933-05-19	1936-09-29	Rhone Poulenc Sa	Manufacture of bases derived from benz-dioxane
US2375138A (en) *	1942-05-01	1945-05-01	American Cyanamid Co	Alkamine esters of aryloxymethyl benzoic acid
US2629736A (en) *	1951-02-24	1953-02-24	Searle & Co	Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
US2730544A (en) *	1952-07-23	1956-01-10	Sahyun Lab	Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
US2750387A (en) *	1953-11-25	1956-06-12	Searle & Co	Basically substituted derivatives of diarylaminobenzamides
US3236891A (en) *	1955-11-29	1966-02-22	Oreal	Nitrophenylenediamine derivatives
US2928833A (en) *	1959-03-03	1960-03-15	S E Massengill Company	Theophylline derivatives
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3454635A (en) *	1965-07-27	1969-07-08	Hoechst Ag	Benzenesulfonyl-ureas and process for their manufacture
US3673241A (en) *	1968-04-04	1972-06-27	Ciba Geigy Corp	Substituted benzaldehyde guanylhydrazones
US3925357A (en) *	1972-07-01	1975-12-09	Takeda Chemical Industries Ltd	' -sulfobenzylpenicillin salt
US4005208A (en) *	1975-05-16	1977-01-25	Smithkline Corporation	N-Heterocyclic-9-xanthenylamines
US4599338A (en) *	1984-01-17	1986-07-08	Adir, S.A.R.L.	Antimigraine 8-[3-(4-aminocarbonyl piperazino and piperidino) propyl[xanthines
US4873330A (en) *	1984-06-25	1989-10-10	Orion-Yhtyma Oy	A process for the preparation of anhydrous, stable, crystalline delta-form of prazosin hydrochloride
US4687777A (en) *	1985-01-19	1987-08-18	Takeda Chemical Industries, Ltd.	Thiazolidinedione derivatives, useful as antidiabetic agents
US5041448A (en) *	1985-06-24	1991-08-20	Janssen Pharmaceutica N.V.	(4-piperidinylmethyl and -hetero) purines
US5258380A (en) *	1985-06-24	1993-11-02	Janssen Pharmaceutica N.V.	(4-piperidinylmethyl and -hetero)purines
US5329025A (en) *	1988-09-21	1994-07-12	G. D. Searle & Co.	3-azido compound
US5234897A (en) *	1989-03-15	1993-08-10	Bayer Aktiengesellschaft	Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
US5051517A (en) *	1989-05-20	1991-09-24	Bayer Aktiengesellschaft	Process for the preparation of herbicidally active 3-amino-5-aminocarbonyl-1,2,4-triazoles
US5223499A (en) *	1989-05-30	1993-06-29	Merck & Co., Inc.	6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5332744A (en) *	1989-05-30	1994-07-26	Merck & Co., Inc.	Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5470579A (en) *	1989-11-28	1995-11-28	Lvmh, Recherche	Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation
US5399578A (en) *	1990-02-19	1995-03-21	Ciba-Geigy Corp	Acyl compounds
US5084460A (en) *	1990-12-24	1992-01-28	A. H. Robins Company, Incorporated	Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
US5266555A (en) *	1991-07-20	1993-11-30	Bayer Aktiengesellschaft	Substituted triazoles
US5300298A (en) *	1992-05-06	1994-04-05	The Pennsylvania Research Corporation	Methods of treating obesity with purine related compounds
US5719279A (en) *	1992-08-10	1998-02-17	Boehringer Ingelheim Kg	Asymmetrically substituted xanthines
US5389642A (en) *	1992-12-16	1995-02-14	Merck Patent Gesellschaft Mit Beschrankter Haftung	Imidazopyridines
US6303661B1 (en) *	1996-04-25	2001-10-16	Probiodrug	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
US5753635A (en) *	1996-08-16	1998-05-19	Berlex Laboratories, Inc.	Purine derivatives and their use as anti-coagulants
US6342601B1 (en) *	1997-12-05	2002-01-29	Astrazeneca Ab	Compounds
US6579868B1 (en) *	1998-01-05	2003-06-17	Eisai Co., Ltd.	Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
US6548481B1 (en) *	1998-05-28	2003-04-15	Probiodrug Ag	Effectors of dipeptidyl peptidase IV
US20070185091A1 (en) *	1999-06-21	2007-08-09	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them
US6784195B2 (en) *	2000-02-05	2004-08-31	Vertex Pharmaceuticals Incorporated	Pyrazole compositions useful as inhibitors of ERK
US20030166578A1 (en) *	2000-06-19	2003-09-04	Arch Jonathan Robert Sanders	Combinations od dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US7235538B2 (en) *	2000-07-04	2007-06-26	Novo Nordisk A/S	Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US20020161001A1 (en) *	2000-07-04	2002-10-31	Kanstrup Anders Bendtz	Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US20040034014A1 (en) *	2000-07-04	2004-02-19	Kanstrup Anders Bendtz	Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US20060173056A1 (en) *	2000-08-10	2006-08-03	Hiroshi Kitajima	Proline derivatives and use thereof as drugs
US7060722B2 (en) *	2000-08-10	2006-06-13	Mitsubishi Pharma Corporation	Proline derivatives and use thereof as drugs
US7074794B2 (en) *	2000-08-10	2006-07-11	Mitsubishi Pharma Corporation	Proline derivatives and the use thereof as drugs
US20020169174A1 (en) *	2000-09-19	2002-11-14	Samuel Chackalamannil	Xanthine phosphodiesterase V inhibitors
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
US20040087587A1 (en) *	2001-02-24	2004-05-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20060205711A1 (en) *	2001-02-24	2006-09-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040077645A1 (en) *	2001-02-24	2004-04-22	Frank Himmelsbach	Xanthine derivatives,production and use thereof as medicament
US20020198205A1 (en) *	2001-02-24	2002-12-26	Frank Himmelsbach	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20060247226A1 (en) *	2001-02-24	2006-11-02	Frank Himmelsbach	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US6869947B2 (en) *	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US20030105077A1 (en) *	2001-07-03	2003-06-05	Kanstrup Anders Bendtz	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US7192952B2 (en) *	2001-07-03	2007-03-20	Novo Nordisk, A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US20030199528A1 (en) *	2001-09-19	2003-10-23	Kanstrup Anders B.	Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV
US20030236272A1 (en) *	2002-01-11	2003-12-25	Carr Richard David	Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
US20030224043A1 (en) *	2002-02-01	2003-12-04	Pfizer Inc.	Immediate release dosage forms containing solid drug dispersions
US20040082570A1 (en) *	2002-02-25	2004-04-29	Eisai Co., Ltd.	Xanthine derivative and DPPIV inhibitor
US7074798B2 (en) *	2002-02-25	2006-07-11	Eisai Co., Ltd	Xanthine derivative and DPPIV inhibitor
US7074923B2 (en) *	2002-05-31	2006-07-11	Schering Corporation	Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
US20030232987A1 (en) *	2002-05-31	2003-12-18	Schering Corporation	Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
US20040116328A1 (en) *	2002-06-06	2004-06-17	Eisai Co., Ltd.	Condensed imidazole derivatives
US20060063787A1 (en) *	2002-06-06	2006-03-23	Eisai Co., Ltd.	Condensed imidazole derivatives
US20060100199A1 (en) *	2002-06-06	2006-05-11	Seiji Yoshikawa	Novel condensed imidazole derivatives
US20040097510A1 (en) *	2002-08-21	2004-05-20	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20080255159A1 (en) *	2002-08-21	2008-10-16	Boehringer Ingelheim Pharma Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20080249089A1 (en) *	2002-08-21	2008-10-09	Boehringer Ingelheim Pharma Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7407955B2 (en) *	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20040166125A1 (en) *	2002-08-22	2004-08-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US20040122228A1 (en) *	2002-08-22	2004-06-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	New purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20060039974A1 (en) *	2002-09-11	2006-02-23	Takeda Pharmaceutical Company Limited	Sustained release preparation
US20040126358A1 (en) *	2002-09-16	2004-07-01	Warne Nicholas W.	Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
US20060094722A1 (en) *	2002-09-26	2006-05-04	Eisai Co., Ltd.	Combination drug
US20040138214A1 (en) *	2002-11-08	2004-07-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138215A1 (en) *	2002-11-21	2004-07-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7109192B2 (en) *	2002-12-03	2006-09-19	Boehringer Ingelheim Pharma Gmbh & Co Kg	Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US20050020574A1 (en) *	2002-12-03	2005-01-27	Boehringer Ingelheim Pharma Gmbh Co. Kg	New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US20050026921A1 (en) *	2003-06-18	2005-02-03	Boehringer Ingelheim International Gmbh	New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US20050032804A1 (en) *	2003-06-24	2005-02-10	Cypes Stephen Howard	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20050070594A1 (en) *	2003-07-31	2005-03-31	Boehringer Ingelheim International Gmbh	Use of angiotensin II receptor antagonists
US20050130985A1 (en) *	2003-11-27	2005-06-16	Boehringer Ingelheim International Gmbh	8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition
US20070219178A1 (en) *	2003-12-04	2007-09-20	Eisai Co., Ltd.	Preventive or therapeutic agents for multiple sclerosis
US20050171093A1 (en) *	2003-12-17	2005-08-04	Boehringer Ingelheim International Gmbh	New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions
US7217711B2 (en) *	2003-12-17	2007-05-15	Boehringer Ingelheim International Gmbh	Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
US20070093659A1 (en) *	2003-12-18	2007-04-26	Jean-Francois Bonfanti	Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
US7183280B2 (en) *	2003-12-23	2007-02-27	Boehringer Ingelheim International Gmbh	Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions
US20050234108A1 (en) *	2004-02-18	2005-10-20	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20050187227A1 (en) *	2004-02-23	2005-08-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US20070142383A1 (en) *	2004-03-13	2007-06-21	Matthias Eckhardt	Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions
US20050203095A1 (en) *	2004-03-13	2005-09-15	Boehringer Ingelheim International Gmbh	Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20070088038A1 (en) *	2004-04-10	2007-04-19	Matthias Eckhardt	2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) *	2004-04-10	2007-02-20	Boehringer Ingelheim International Gmbh	2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US20050261352A1 (en) *	2004-05-10	2005-11-24	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US20050266080A1 (en) *	2004-05-28	2005-12-01	Desai Divyakant S	Coated tablet formulation and method
US20060004074A1 (en) *	2004-06-24	2006-01-05	Boehringer Ingelheim International Gmbh	New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20060058323A1 (en) *	2004-09-11	2006-03-16	Boehringer Ingelheim International Gmbh	New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060079541A1 (en) *	2004-09-14	2006-04-13	Boehringer Ingelheim International Gmbh	3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060142310A1 (en) *	2004-11-05	2006-06-29	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US20070027168A1 (en) *	2005-07-30	2007-02-01	Waldemar Pfrengle	8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US20070281940A1 (en) *	2006-05-04	2007-12-06	Klaus Dugi	Uses of dpp-iv inhibitors

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9108964B2 (en)	2002-08-21	2015-08-18	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10023574B2 (en)	2002-08-21	2018-07-17	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20080255159A1 (en) *	2002-08-21	2008-10-16	Boehringer Ingelheim Pharma Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en)	2002-08-21	2017-01-31	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US8178541B2 (en)	2002-08-21	2012-05-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8664232B2 (en)	2002-08-21	2014-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9321791B2 (en)	2002-08-21	2016-04-26	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10202383B2 (en)	2002-08-21	2019-02-12	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8119648B2 (en)	2002-08-21	2012-02-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20090131432A1 (en) *	2002-08-22	2009-05-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivates, their preparation and their use in pharmaceutical compositions
US7838529B2 (en)	2002-08-22	2010-11-23	Boehringer Ingelheim International Gmbh	Xanthine derivates, their preparation and their use in pharmaceutical compositions
US20100144703A1 (en) *	2002-11-08	2010-06-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US8697868B2 (en)	2004-02-18	2014-04-15	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20090137801A1 (en) *	2004-02-18	2009-05-28	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7667035B2 (en)	2004-05-10	2010-02-23	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US7906539B2 (en)	2004-06-24	2011-03-15	Boehringer Ingelheim International Gmbh	Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20080312243A1 (en) *	2004-06-24	2008-12-18	Matthias Eckhardt	Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US9499546B2 (en)	2004-11-05	2016-11-22	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9751855B2 (en)	2004-11-05	2017-09-05	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US20090192314A1 (en) *	2004-11-05	2009-07-30	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US8883805B2 (en)	2004-11-05	2014-11-11	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US7820815B2 (en)	2004-11-05	2010-10-26	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US8541450B2 (en)	2004-11-05	2013-09-24	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US20060142310A1 (en) *	2004-11-05	2006-06-29	Boehringer Ingelheim International Gmbh	Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US8106060B2 (en)	2005-07-30	2012-01-31	Boehringer Ingelheim International Gmbh	8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8637530B2 (en)	2005-07-30	2014-01-28	Boehringer Ingelheim International Gmbh	8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US9266888B2 (en)	2006-05-04	2016-02-23	Boehringer Ingelheim International Gmbh	Polymorphs
US8232281B2 (en)	2006-05-04	2012-07-31	Boehringer Ingelheim International Gmbh	Uses of DPP-IV inhibitors
US12171767B2 (en)	2006-05-04	2024-12-24	Boehringer Ingelheim International Gmbh	Uses of DPP IV inhibitors
US11033552B2 (en)	2006-05-04	2021-06-15	Boehringer Ingelheim International Gmbh	DPP IV inhibitor formulations
US11291668B2 (en)	2006-05-04	2022-04-05	Boehringer Ingelheim International Gmbh	Uses of DPP IV inhibitors
US10301313B2 (en)	2006-05-04	2019-05-28	Boehringer Ingelheim International Gmbh	Polymorphs
US11084819B2 (en)	2006-05-04	2021-08-10	Boehringer Ingelheim International Gmbh	Polymorphs
US8673927B2 (en)	2006-05-04	2014-03-18	Boehringer Ingelheim International Gmbh	Uses of DPP-IV inhibitors
US10080754B2 (en)	2006-05-04	2018-09-25	Boehringer Ingelheim International Gmbh	Uses of DPP IV inhibitors
US9493462B2 (en)	2006-05-04	2016-11-15	Boehringer Ingelheim International Gmbh	Polymorphs
US12178819B2 (en)	2006-05-04	2024-12-31	Boehringer Ingelheim International Gmbh	DPP IV inhibitor formulations
US20070259900A1 (en) *	2006-05-04	2007-11-08	Peter Sieger	Polymorphs
US9815837B2 (en)	2006-05-04	2017-11-14	Boehringer Ingelheim International Gmbh	Polymorphs
US11919903B2 (en)	2006-05-04	2024-03-05	Boehringer Ingelheim International Gmbh	Polymorphs
US9173859B2 (en)	2006-05-04	2015-11-03	Boehringer Ingelheim International Gmbh	Uses of DPP IV inhibitors
US8071583B2 (en)	2006-08-08	2011-12-06	Boehringer Ingelheim International Gmbh	Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
US8551957B2 (en)	2007-08-16	2013-10-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US20110195917A1 (en) *	2007-08-16	2011-08-11	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US9155705B2 (en)	2008-04-03	2015-10-13	Boehringer Ingelheim International Gmbh	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10022379B2 (en)	2008-04-03	2018-07-17	Boehringer Ingelheim International Gmbh	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en)	2008-04-03	2021-04-13	Boehringer Ingelheim International Gmbh	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9415016B2 (en)	2008-04-03	2016-08-16	Boehringer Ingelheim International Gmbh	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9486526B2 (en)	2008-08-06	2016-11-08	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients inappropriate for metformin therapy
US8853156B2 (en)	2008-08-06	2014-10-07	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients inappropriate for metformin therapy
US10034877B2 (en)	2008-08-06	2018-07-31	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients inappropriate for metformin therapy
US20110152342A1 (en) *	2008-08-14	2011-06-23	Hiroshi Uchida	Stabilized pharmaceutical composition
US8513264B2 (en)	2008-09-10	2013-08-20	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
US11911388B2 (en)	2008-10-16	2024-02-27	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US9212183B2 (en)	2008-12-23	2015-12-15	Boehringer Ingelheim International Gmbh	Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US8865729B2 (en)	2008-12-23	2014-10-21	Boehringer Ingelheim International Gmbh	Salt forms of a xanthine compound
US8846695B2 (en)	2009-01-07	2014-09-30	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US10406172B2 (en)	2009-02-13	2019-09-10	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US12115179B2 (en)	2009-02-13	2024-10-15	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20100209506A1 (en) *	2009-02-13	2010-08-19	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US10555939B2 (en)	2009-05-19	2020-02-11	Celgene Corporation	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US8802842B2 (en)	2009-09-30	2014-08-12	Boehringer Ingelheim International Gmbh	Method for the preparation of a crystalline form
US9873714B2 (en)	2009-09-30	2018-01-23	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US20110237526A1 (en) *	2009-09-30	2011-09-29	Boehringer Ingelheim International Gmbh	Method for the preparation of a crystalline form
US10610489B2 (en)	2009-10-02	2020-04-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
EP2482812B1 (en)	2009-10-02	2023-01-11	Boehringer Ingelheim International GmbH	Pharmaceutical compositions comprising bi-1356 and metformin
US20110236477A1 (en) *	2009-10-02	2011-09-29	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US10092571B2 (en)	2009-11-27	2018-10-09	Boehringer Ingelheim International Gmbh	Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9457029B2 (en)	2009-11-27	2016-10-04	Boehringer Ingelheim International Gmbh	Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9603851B2 (en)	2010-05-05	2017-03-28	Boehringer Ingelheim International Gmbh	Combination therapy
US9186392B2 (en)	2010-05-05	2015-11-17	Boehringer Ingelheim International Gmbh	Combination therapy
US10004747B2 (en)	2010-05-05	2018-06-26	Boehringer Ingelheim International Gmbh	Combination therapy
US9149478B2 (en)	2010-06-24	2015-10-06	Boehringer Ingelheim International Gmbh	Diabetes therapy
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
US11911387B2 (en)	2010-11-15	2024-02-27	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
US11564886B2 (en)	2011-03-07	2023-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions
US10596120B2 (en)	2011-03-07	2020-03-24	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions
US20180185291A1 (en)	2011-03-07	2018-07-05	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions
US8962636B2 (en)	2011-07-15	2015-02-24	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9199998B2 (en)	2011-07-15	2015-12-01	Boehringer Ingelheim Internatioal Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US10195203B2 (en)	2012-05-14	2019-02-05	Boehringr Ingelheim International GmbH	Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US12312352B2 (en)	2012-05-14	2025-05-27	Boehringer Ingelheim International Gmbh	Use of a DPP-4 inhibitor in SIRS and/or sepsis
US9526730B2 (en)	2012-05-14	2016-12-27	Boehringer Ingelheim International Gmbh	Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9713618B2 (en)	2012-05-24	2017-07-25	Boehringer Ingelheim International Gmbh	Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9949997B2 (en)	2013-04-05	2018-04-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US10258637B2 (en)	2013-04-05	2019-04-16	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11833166B2 (en)	2013-04-05	2023-12-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11090323B2 (en)	2013-04-05	2021-08-17	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US12433906B2 (en)	2013-04-05	2025-10-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11918596B2 (en)	2013-04-05	2024-03-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9949998B2 (en)	2013-04-05	2018-04-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11666590B2 (en)	2013-04-18	2023-06-06	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US12427162B2 (en)	2013-04-18	2025-09-30	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
US20150283248A1 (en) *	2014-04-02	2015-10-08	Aurobindo Pharma Ltd.	Pharmaceutical compositions of Linagliptin and process for preparation thereof
US10548848B2 (en) *	2015-06-17	2020-02-04	Hexal Ag	Alogliptin formulation
US10155000B2 (en)	2016-06-10	2018-12-18	Boehringer Ingelheim International Gmbh	Medical use of pharmaceutical combination or composition
US12364700B2 (en)	2016-06-10	2025-07-22	Boehringer Ingelheim International Gmbh	Medical use of pharmaceutical combination or composition
US12263153B2 (en)	2016-11-10	2025-04-01	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof

Also Published As

Publication number	Publication date
MX358617B (es)	2018-08-29
HRP20100507T1 (hr)	2010-10-31
ME01170B (me)	2013-03-20
SI2023902T1 (sl)	2011-01-31
SG171649A1 (en)	2011-06-29
JP2016104811A (ja)	2016-06-09
US20190209571A1 (en)	2019-07-11
AU2007247193A1 (en)	2007-11-15
US11033552B2 (en)	2021-06-15
MX2008013958A (es)	2008-11-12
JP2012072187A (ja)	2012-04-12
SI2283819T1 (sl)	2015-01-30
US20130122089A1 (en)	2013-05-16
BRPI0722388A2 (pt)	2015-05-19
ECSP088800A (es)	2008-11-27
TWI520753B (zh)	2016-02-11
EA029890B1 (ru)	2018-05-31
KR20090009226A (ko)	2009-01-22
TW200812648A (en)	2008-03-16
US20250064818A1 (en)	2025-02-27
US20120003313A1 (en)	2012-01-05
PT2023902E (pt)	2010-10-12
NO20084256L (no)	2008-12-02
KR20150100957A (ko)	2015-09-02
PT2283819E (pt)	2014-11-03
KR102051281B9 (ko)	2024-08-12
ES2527409T3 (es)	2015-01-23
IL212841A0 (en)	2011-07-31
JP7084711B2 (ja)	2022-06-15
ES2527409T4 (es)	2015-03-11
CN102526737B (zh)	2015-02-25
EP2283819B1 (en)	2014-10-08
JP2024074800A (ja)	2024-05-31
JP2013227338A (ja)	2013-11-07
ATE480228T1 (de)	2010-09-15
JP2022075826A (ja)	2022-05-18
ME01941B (me)	2015-05-20
NZ595983A (en)	2013-08-30
NZ572862A (en)	2011-11-25
IL195030A0 (en)	2009-08-03
EP2023902B1 (en)	2010-09-08
EA201100958A1 (ru)	2012-04-30
JP5478244B2 (ja)	2014-04-23
DE602007009091D1 (de)	2010-10-21
EP2023902A1 (en)	2009-02-18
MY146969A (en)	2012-10-15
KR101710881B1 (ko)	2017-02-28
PL2023902T4 (pl)	2011-06-30
PL2283819T3 (pl)	2015-03-31
EA016559B1 (ru)	2012-05-30
AR079930A2 (es)	2012-02-29
EP2283819A1 (en)	2011-02-16
AU2007247193B2 (en)	2013-05-16
CL2012002521A1 (es)	2012-12-21
JP2009535376A (ja)	2009-10-01
ES2538818T3 (es)	2015-06-24
KR101855323B1 (ko)	2018-05-09
CA2649922C (en)	2014-02-04
BRPI0722388B1 (pt)	2022-09-27
HK1172549A1 (en)	2013-04-26
US20210260068A1 (en)	2021-08-26
CA2649922A1 (en)	2007-11-15
HRP20150003T1 (xx)	2015-03-13
US20170312287A1 (en)	2017-11-02
DK2277509T5 (da)	2015-06-08
CN101437493B (zh)	2013-10-23
NZ613426A (en)	2015-02-27
CY1116064T1 (el)	2017-02-08
AR060755A1 (es)	2008-07-10
TWI474843B (zh)	2015-03-01
JP6564720B2 (ja)	2019-08-21
EP2910241A1 (en)	2015-08-26
WO2007128724A1 (en)	2007-11-15
PE20110666A1 (es)	2011-09-23
PL2277509T3 (pl)	2015-07-31
EP2277509B1 (en)	2015-03-11
EP2277509A1 (en)	2011-01-26
HRP20150003T2 (hr)	2015-12-18
EP2283819B9 (en)	2015-03-11
PL2023902T3 (pl)	2011-03-31
DK2283819T3 (da)	2015-01-05
US12178819B2 (en)	2024-12-31
MX384206B (es)	2025-03-14
IL195030A (en)	2013-09-30
EP2023902B8 (en)	2010-11-24
JP2018021082A (ja)	2018-02-08
BRPI0711179B1 (pt)	2022-02-08
KR101478983B1 (ko)	2015-01-05
RS51466B (sr)	2011-04-30
UY30319A1 (es)	2008-01-02
ES2348576T3 (es)	2010-12-09
ZA200808361B (en)	2010-10-27
RS53570B1 (sr)	2015-02-27
DK2277509T3 (da)	2015-04-13
UA94942C2 (ru)	2011-06-25
HUE025210T2 (en)	2016-03-29
CN102526737A (zh)	2012-07-04
DK2023902T3 (da)	2010-11-15
BRPI0711179A2 (pt)	2011-05-03
NO343067B1 (no)	2018-10-22
CY1111354T1 (el)	2015-08-05
KR101855323B9 (ko)	2025-10-15
EP1852108A1 (en)	2007-11-07
CN101437493A (zh)	2009-05-20
US20120219622A1 (en)	2012-08-30
KR20170141812A (ko)	2017-12-26
JP6987908B2 (ja)	2022-01-05
HK1130442A1 (en)	2009-12-31
TW201417844A (zh)	2014-05-16
PE20080698A1 (es)	2008-08-04
EA200802184A1 (ru)	2009-06-30
CL2012002522A1 (es)	2012-12-21
MY148496A (en)	2013-04-30
KR20160128446A (ko)	2016-11-07
KR20140063896A (ko)	2014-05-27
US20160022687A1 (en)	2016-01-28
JP2020079316A (ja)	2020-05-28
KR102051281B1 (ko)	2019-12-03
JP6100998B2 (ja)	2017-03-22

Publication	Publication Date	Title
US12178819B2 (en)	2024-12-31	DPP IV inhibitor formulations
JP2009535376A6 (ja)	2010-11-18	Ｄｐｐｉｖインヒビター製剤
JP2013227338A6 (ja)	2014-01-16	Ｄｐｐｉｖインヒビター製剤
HK1172549B (en)	2015-12-18	Dpp iv inhibitor formulations
HK1130442B (en)	2014-07-11	Dpp iv inhibitor formulations

Legal Events

Date	Code	Title	Description
2010-07-13	AS	Assignment	Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOHLRAUSCH, ANJA;ROMER, PATRICK;SEIFFERT, GERD;SIGNING DATES FROM 20070606 TO 20070711;REEL/FRAME:024670/0665
2011-10-08	STCB	Information on status: application discontinuation	Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

Date

Code

Title

Description

2010-07-13

Assignment

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOHLRAUSCH, ANJA;ROMER, PATRICK;SEIFFERT, GERD;SIGNING DATES FROM 20070606 TO 20070711;REEL/FRAME:024670/0665

2011-10-08

STCB

Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION